key: cord-0017265-qc8wvz73 authors: Kohli, Mikashmi; Schiller, Ian; Dendukuri, Nandini; Yao, Mandy; Dheda, Keertan; Denkinger, Claudia M; Schumacher, Samuel G; Steingart, Karen R title: Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults date: 2021-01-15 journal: Cochrane Database Syst Rev DOI: 10.1002/14651858.cd012768.pub3 sha: a304968e68f87994227efb730e48068c7b23bda0 doc_id: 17265 cord_uid: qc8wvz73 BACKGROUND: Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely used for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum. To extend our previous review on extrapulmonary tuberculosis (Kohli 2018), we performed this update to inform updated WHO policy (WHO Consolidated Guidelines (Module 3) 2020). OBJECTIVES: To estimate diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin resistance in adults with presumptive extrapulmonary tuberculosis. SEARCH METHODS: Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American Caribbean Health Sciences Literature, Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the International Standard Randomized Controlled Trial Number Registry, and ProQuest, 2 August 2019 and 28 January 2020 (Xpert Ultra studies), without language restriction. SELECTION CRITERIA: Cross‐sectional and cohort studies using non‐respiratory specimens. Forms of extrapulmonary tuberculosis: tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, disseminated tuberculosis. Reference standards were culture and a study‐defined composite reference standard (tuberculosis detection); phenotypic drug susceptibility testing and line probe assays (rifampicin resistance detection). DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data and assessed risk of bias and applicability using QUADAS‐2. For tuberculosis detection, we performed separate analyses by specimen type and reference standard using the bivariate model to estimate pooled sensitivity and specificity with 95% credible intervals (CrIs). We applied a latent class meta‐analysis model to three forms of extrapulmonary tuberculosis. We assessed certainty of evidence using GRADE. MAIN RESULTS: 69 studies: 67 evaluated Xpert MTB/RIF and 11 evaluated Xpert Ultra, of which nine evaluated both tests. Most studies were conducted in China, India, South Africa, and Uganda. Overall, risk of bias was low for patient selection, index test, and flow and timing domains, and low (49%) or unclear (43%) for the reference standard domain. Applicability for the patient selection domain was unclear for most studies because we were unsure of the clinical settings. Cerebrospinal fluid Xpert Ultra (6 studies) Xpert Ultra pooled sensitivity and specificity (95% CrI) against culture were 89.4% (79.1 to 95.6) (89 participants; low‐certainty evidence) and 91.2% (83.2 to 95.7) (386 participants; moderate‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 168 would be Xpert Ultra‐positive: of these, 79 (47%) would not have tuberculosis (false‐positives) and 832 would be Xpert Ultra‐negative: of these, 11 (1%) would have tuberculosis (false‐negatives). Xpert MTB/RIF (30 studies) Xpert MTB/RIF pooled sensitivity and specificity against culture were 71.1% (62.8 to 79.1) (571 participants; moderate‐certainty evidence) and 96.9% (95.4 to 98.0) (2824 participants; high‐certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 99 would be Xpert MTB/RIF‐positive: of these, 28 (28%) would not have tuberculosis; and 901 would be Xpert MTB/RIF‐negative: of these, 29 (3%) would have tuberculosis. Pleural fluid Xpert Ultra (4 studies) Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) (158 participants; very low‐certainty evidence) and 87.0% (63.1 to 97.9) (240 participants; very low‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 192 would be Xpert Ultra‐positive: of these, 117 (61%) would not have tuberculosis; and 808 would be Xpert Ultra‐negative: of these, 25 (3%) would have tuberculosis. Xpert MTB/RIF (25 studies) Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) (644 participants; low‐certainty evidence) and 98.9% (97.6 to 99.7) (2421 participants; high‐certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 60 would be Xpert MTB/RIF‐positive: of these, 10 (17%) would not have tuberculosis; and 940 would be Xpert MTB/RIF‐negative: of these, 50 (5%) would have tuberculosis. Lymph node aspirate Xpert Ultra (1 study) Xpert Ultra sensitivity and specificity (95% confidence interval) against composite reference standard were 70% (51 to 85) (30 participants; very low‐certainty evidence) and 100% (92 to 100) (43 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 70 would be Xpert Ultra‐positive and 0 (0%) would not have tuberculosis; 930 would be Xpert Ultra‐negative and 30 (3%) would have tuberculosis. Xpert MTB/RIF (4 studies) Xpert MTB/RIF pooled sensitivity and specificity against composite reference standard were 81.6% (61.9 to 93.3) (377 participants; low‐certainty evidence) and 96.4% (91.3 to 98.6) (302 participants; low‐certainty evidence). Of 1000 people where 100 have lymph node tuberculosis, 118 would be Xpert MTB/RIF‐positive and 37 (31%) would not have tuberculosis; 882 would be Xpert MTB/RIF‐negative and 19 (2%) would have tuberculosis. In lymph node aspirate, Xpert MTB/RIF pooled specificity against culture was 86.2% (78.0 to 92.3), lower than that against a composite reference standard. Using the latent class model, Xpert MTB/RIF pooled specificity was 99.5% (99.1 to 99.7), similar to that observed with a composite reference standard. Rifampicin resistance Xpert Ultra (4 studies) Xpert Ultra pooled sensitivity and specificity were 100.0% (95.1 to 100.0), (24 participants; low‐certainty evidence) and 100.0% (99.0 to 100.0) (105 participants; moderate‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 100 would be Xpert Ultra‐positive (resistant): of these, zero (0%) would not have rifampicin resistance; and 900 would be Xpert Ultra‐negative (susceptible): of these, zero (0%) would have rifampicin resistance. Xpert MTB/RIF (19 studies) Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9 to 98.8) (148 participants; high‐certainty evidence) and 99.1% (98.0 to 99.7) (822 participants; high‐certainty evidence). Of 1000 people where 100 have rifampicin resistance, 105 would be Xpert MTB/RIF‐positive (resistant): of these, 8 (8%) would not have rifampicin resistance; and 895 would be Xpert MTB/RIF‐negative (susceptible): of these, 3 (0.3%) would have rifampicin resistance. AUTHORS' CONCLUSIONS: Xpert Ultra and Xpert MTB/RIF may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across different extrapulmonary specimens: while for most specimens specificity is high, the tests rarely yield a positive result for people without tuberculosis. For tuberculous meningitis, Xpert Ultra had higher sensitivity and lower specificity than Xpert MTB/RIF against culture. Xpert Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance. Future research should acknowledge the concern associated with culture as a reference standard in paucibacillary specimens and consider ways to address this limitation. Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity. a There were few participants in this analysis. The very wide 95% CrI around true-positives and false-negatives may lead to di erent decisions, depending on which credible limits are assumed. We downgraded two levels for imprecision. b The wide 95% CrI around true-negatives and false-positives would likely lead to di erent decisions, depending on which credible limits are assumed. We downgraded one level for imprecision. c The wide 95% CrI around true-positives and false-negatives may lead to di erent decisions, depending on which credible limits are assumed. We downgraded one level for imprecision. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. Very low: we have very little confidence in the e ect estimate: the true e ect is likely to be substantially di erent from the estimate of e ect. The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. Prevalence of 10% Prevalence of 20% We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was 46.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 19.8%. a We were interested in how Xpert Ultra performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness. b For individual studies, sensitivity estimates ranged from 48% to 84%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency. c There was a low number of participants contributing to this analysis for the observed sensitivity. As we had already downgraded for inconsistency, we downgraded one level for imprecision. d For individual studies, specificity estimates ranged from 65% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency. e We thought the wide 95% CrI around false-positives and true-negatives would likely lead to di erent decisions depending on which confidence limits are assumed. As we had already downgraded for inconsistency, we downgraded one level for imprecision. f We were interested in how Xpert MTB/RIF performed in participants presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However, most studies did not report information on the clinical setting. We downgraded one level for indirectness. g For individual studies, sensitivity estimates ranged from 10% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for inconsistency. h As we had already downgraded for inconsistency, we did not downgrade further for imprecision. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. Abbreviations: Crl: credible interval; TB: tuberculosis. We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the prevalence of tuberculosis in the included study was 41%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 55.5%. a We identified only one study, which was conducted at a tertiary referral centre in South Africa, a high TB burden country. Most participants (84%) were seen as outpatients. With only one study, applicability to other settings comes with some uncertainty. We downgraded one level for indirectness. b There were very few participants contributing to this analysis. The 95% CI was very wide. We downgraded two levels for imprecision. c There were very few participants contributing to this analysis. The 95% CI was wide. We downgraded two levels for imprecision. d The composite reference standard was defined by the primary study authors and therefore, was not uniform. We downgraded one level for risk of bias. e For indirectness, regarding applicability, for the patient population, we considered most studies to have unclear concern. We were interested in how Xpert MTB/RIF performed in patients presumed to have extrapulmonary TB who were evaluated as they would be in routine practice. However, none of the studies reported this information. We downgraded one level for indirectness. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Low: our confidence in the e ect estimate is limited: the true e ect may be substantially di erent from the estimate of the e ect. Very low: we have very little confidence in the e ect estimate: the true e ect is likely to be substantially di erent from the estimate of e ect. The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure. We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of rifampicin resistance in the included studies was 19.2%. For Xpert MTB/RIF, the median prevalence of rifampicin resistance in the included studies was 11.9%. a All these studies were conducted in China (high TB-burden country). Applicability to other settings comes with some uncertainty and therefore we downgraded one level for indirectness. b There was a low number of participants contributing to this analysis for the observed sensitivity. We downgraded one level for imprecision. GRADE certainty of the evidence High: we are very confident that the true e ect lies close to that of the estimate of the e ect. Moderate: we are moderately confident in the e ect estimate: the true e ect is likely to be close to the estimate of the e ect, but there is a possibility that it is substantially di erent. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Tuberculosis (TB) causes tremendous su ering worldwide and has surpassed HIV/AIDS as the world's leading infectious cause of death. The World Health Organization (WHO) estimates that globally in 2019, 10.0 million (range, 8.9 to 11.0 million) people fell ill with tuberculosis. In 2019, around 1.2 million HIV-negative people died from tuberculosis and 208,000 HIV-positive people died from tuberculosis (WHO Global TB Report 2020). When people receive proper treatment, tuberculosis is treatable and curable. The WHO estimates that from 2000 to 2019 more than 60 million lives were saved by diagnosing and treating tuberculosis. However, the COVID-19 pandemic threatens the gains made over recent years. A modelling study by the WHO suggests that there could be between 200,000 and 400,000 additional tuberculosis deaths in 2020 if, over a period of three months, 25% to 50% fewer people were detected and treated with tuberculosis (WHO Global TB Report 2020). Of the 7.1 million new cases of tuberculosis notified to the WHO in 2019, 16% were cases of extrapulmonary tuberculosis, (range, 8% in the WHO Western Pacific Region to 24% in the WHO Eastern Mediterranean Region) (WHO Global TB Report 2020). Among countries in the European Union, extrapulmonary tuberculosis was responsible for 19% of all notified cases (range, 6% to 44%) (Sandgren 2013). A large retrospective analysis from China found that of 19,279 hospitalised tuberculosis patients, around 33% had extrapulmonary tuberculosis (Pang 2019). The number of people a ected by extrapulmonary tuberculosis is likely to be higher, given that, according to the WHO, extrapulmonary tuberculosis is notified as pulmonary tuberculosis when the two forms exist together, and diagnosing extrapulmonary tuberculosis is challenging, as described below. Additionally, extrapulmonary tuberculosis accounts for an increasing proportion of tuberculosis cases in some countries, in part because of host and genetic considerations, and the association of extrapulmonary tuberculosis and HIV (Golden 2005; Pai 2016; Perkins 2007; Webster 2014) . Based on surveillance and epidemiological data, extrapulmonary tuberculosis a ects a greater proportion of children than adults (Nelson 2004) . Drug-resistant tuberculosis is a serious threat to global health. For the purpose of surveillance and treatment, drug-resistant tuberculosis is classified as rifampicin-resistant tuberculosis, multidrug-resistant tuberculosis (MDR-TB), and extensively drugresistant tuberculosis. MDR-TB is defined as resistance to at least isoniazid and rifampicin, the two most important first-line anti-tuberculosis drugs. Extensively drug-resistant tuberculosis is defined as MDR-TB plus resistance to at least one drug in the following two classes of medicines used in treatment of MDR-TB: fluoroquinolones and second-line injectable agents. In 2019, there were approximately half a million new cases of rifampicin-resistant tuberculosis (of which 78% had MDR-TB), with India (27%), China (14%) and the Russian Federation (9%) accounting for the largest burden (WHO Global TB Report 2020). In 2019, 12,350 cases of extensively drug-resistant tuberculosis were reported (WHO Global TB Report 2020). In 2014, the World Health Assembly unanimously approved the WHO End TB Strategy, a 20-year strategy devised to end the global tuberculosis epidemic (WHO END TB 2014). Early diagnosis of tuberculosis, including universal drug susceptibility testing (DST) and systematic screening of contacts and high-risk groups, is a part of pillar one of the strategy. Tuberculosis is caused by infection with Mycobacterium tuberculosis (M tuberculosis) bacteria. Tuberculosis predominantly a ects the lungs (pulmonary tuberculosis). Extrapulmonary tuberculosis refers to tuberculosis in parts of the body other than the lungs. Extrapulmonary tuberculosis is known to a ect virtually every part of the body, with lymph nodes and the pleura being the most common sites (Sharma 2004) . Although active pulmonary tuberculosis is transmissible by droplets spread by coughing, extrapulmonary tuberculosis is thought to result from hematogenous spread (spread by way of the bloodstream) from an initial lung infection and is not infectious. Extrapulmonary tuberculosis can occur alone or together with pulmonary tuberculosis. The various forms of extrapulmonary tuberculosis cause signs and symptoms related to the structures a ected. Table 1 describes the forms of extrapulmonary tuberculosis included in this review, as well as the respective specimens that may be collected for diagnosis. Diagnosis of extrapulmonary tuberculosis is challenging for several reasons. Many forms of extrapulmonary tuberculosis require invasive diagnostic sampling; gathering adequate specimens can pose risk of harm to the patient and can be costly. Most forms of extrapulmonary tuberculosis are paucibacillary (tuberculosis disease caused by a small number of bacteria), making diagnosis by various tests less sensitive. Culture, for example, has reduced sensitivity in paucibacillary disease. In addition, culture takes several weeks for results and requires a highly-equipped laboratory. Limitations are also associated with histology, which relies on highly-trained operators, and characteristic morphology is shared with other diseases. As a result of these di iculties, diagnosis of extrapulmonary tuberculosis is o en made on the grounds of clinical suspicion alone, and many people receive the wrong diagnosis, leading to unnecessary tuberculosis treatment or poor outcomes from untreated extrapulmonary tuberculosis. Tuberculosis treatment regimens must contain multiple drugs to which the organisms are sensitive to cure tuberculosis and avoid selection for drug resistance. WHO tuberculosis treatment guidelines recommend the same drug regimens for extrapulmonary and pulmonary disease, with notable mention of tuberculous meningitis and bone or joint tuberculosis, for which longer treatment regimens are recommended (WHO 2010; WHO 2017; WHO Compendium 2018) . For patients with tuberculous meningitis or tuberculous pericarditis, the use of adjuvant corticosteroid therapy is recommended in addition to appropriate tuberculosis treatment regimens (WHO 2017; WHO Compendium 2018) . Other tuberculosis treatment guidelines include Sharma 2017b (India), and those issued by the American Thoracic Society, the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (Nahid 2016). The drugs used to treat MDR-TB are less potent and more toxic than the drugs used to treat drug-susceptible tuberculosis, historically requiring two years or more of therapy. However, in December 2019, based on new evidence on the management of drug-resistant tuberculosis, the WHO issued recommendations that all patients with MDR-TB or rifampicin-resistant tuberculosis, including those who are also The index tests, Xpert MTB/RIF and Ultra Xpert MTB/RIF (Xpert Ultra, the newest version) (Cepheid Inc, Sunnyvale, USA), are nucleic acid amplification tests (NAATs) (i.e. molecular tests) used for diagnosing tuberculosis and rifampicin-resistant tuberculosis. Xpert MTB/RIF and Xpert Ultra cartridges are used with the GeneXpert system (Cepheid 2018; Cepheid 2019). Xpert MTB/RIF and Xpert Ultra are able to detect both M tuberculosis complex and rifampicin resistance within two hours a er starting the test, with minimal hands-on technical time. Unlike conventional NAATs, with Xpert MTB/RIF and Xpert Ultra, sample processing and polymerase chain reaction (PCR) amplification and detection are integrated into a single, self-enclosed test unit, the GeneXpert cartridge. Following sample loading, all steps in the assay are completely automated and self-contained. In addition, the assays' sample reagent, used to liquefy sputum, has potent tuberculocidal (the ability to kill tuberculosis bacteria) properties and so largely eliminates biosafety concerns during the test procedure (Banada 2010). Except as described below for Ultra trace call results, a single Xpert MTB/RIF or Xpert Ultra run will provide both detection of tuberculosis and detection of rifampicin resistance. One cannot deselect testing for rifampicin resistance and only run the assay for tuberculosis detection. The development of Xpert MTB/RIF was a major step toward improving detection of tuberculosis and rifampicin resistance globally (Boehme 2010; Small 2011). Since Xpert MTB/RIF was released, there have been four generations (G1, G2, G3, and G4) of the test involving di erent so ware and cartridge combinations. Although in comparison with smear microscopy Xpert MTB/RIF has increased sensitivity for pulmonary tuberculosis (Steingart 2014) , the test has suboptimal sensitivity in people with smearnegative and HIV-associated tuberculosis. A Cochrane Review on the diagnostic accuracy of Xpert MTB/RIF for pulmonary tuberculosis found pooled sensitivity and specificity (95% credible Interval (CrI)) of 85% (82% to 88%) and 98% (97% to 98%), (70 studies, 37,237 unselected participants; high-certainty evidence) (Horne 2019). However, Xpert MTB/RIF sensitivity was decreased in people with smear-negative culture-positive disease, pooled sensitivity of 67% (62% to 72%), and people living with HIV, pooled sensitivity of 81% (75% to 86%) (Horne 2019). Xpert MTB/RIF versions have also had some limitations in detecting rifampicin resistance. In order to overcome limitations with Xpert MTB/RIF, Cepheid developed Xpert Ultra, a re-engineered assay that uses a newly-developed cartridge but may be run on the same device a er a so ware upgrade. To improve sensitivity for tuberculosis detection, Xpert Ultra incorporates two di erent multi-copy amplification targets and a larger DNA reaction chamber than Xpert MTB/RIF ( WHO Xpert Ultra 2017) . A laboratory study reported that the limit of detection (the lowest number of colony-forming units (CFUs) per sample that can be reproducibly distinguished from negative samples with 95% confidence) using Xpert Ultra improved to 15.6 CFU/mL of sputum compared to 112.6 CFU/mL for Xpert MTB/RIF (Chakravorty 2017). Xpert Ultra has added a new result category, 'trace call', that corresponds to the lowest bacillary load for M tuberculosis detection ( WHO Xpert Ultra 2017) . This new category is reported as 'MTB trace DETECTED'. Interpreting a trace call result requires a reassessment of clinical symptoms and history of prior tuberculosis. No rifampicin resistance results are available (indeterminate) for people with trace results. As with Xpert MTB/RIF (Miotto 2012), Xpert Ultra detects both live and dead bacteria. To address limitations in rifampicin resistance detection, Xpert Ultra uses melting temperature-based analysis, in lieu of realtime PCR analysis with Xpert MTB/RIF. Melting temperaturebased analysis allows Xpert Ultra to better distinguish resistanceconferring mutations from silent mutations with improved diagnostic accuracy for rifampicin resistance detection (Global Laboratory Initiative 2017). For sputum specimens, the test procedure may be used either directly on raw sputum specimens or sputum pellets created a er decontaminating and concentrating the sputum (Blakemore 2010). In both cases, the test material is combined with the assay sample reagent (sodium hydroxide and isopropanol), mixed by hand or vortex, and incubated at room temperature for 15 minutes. A er the incubation step, 2 mL of the treated specimen are transferred to the cartridge and the run is initiated (Helb 2010). According to the manufacturer, as with Xpert MTB/RIF, Xpert Ultra may be used with fresh sputum specimens, which may be either unprocessed sputum or processed sputum sediments. The sample reagent:sample volume ratio is 2:1 for unprocessed sputum and 3:1 for sputum pellets. The manufacturer does not specifically mention the use of the index tests with frozen specimens (Cepheid 2018; Cepheid 2019 Before a specimen is tested, patients with presumptive extrapulmonary tuberculosis would have undergone a health examination (history and physical examination) and possibly a chest radiograph. The presentation of extrapulmonary tuberculosis varies depending on the body site a ected, and it may imitate other diseases, such as cancer and bacterial and fungal infections. Signs and symptoms of extrapulmonary tuberculosis are o en non-specific and may include fever, night sweats, fatigue, loss of appetite, and weight loss (as seen in pulmonary tuberculosis) or specific complaints related to the involved site (e.g. headache for tuberculous meningitis, back pain for tuberculosis of the spine). The clinical presentation of extrapulmonary disease may be acute but is more o en subacute (falling between acute and chronic) or chronic, meaning that patients may have symptoms for days to months before they seek care. We have described in Table 1 The downstream consequences of testing include the following. • True-positive (TP): patients would benefit from rapid diagnosis and appropriate treatment. • True-negative (TN): patients would be spared unnecessary treatment and would benefit from reassurance and pursuit of an alternative diagnosis. • False-positive (FP): patients would likely experience anxiety and morbidity caused by additional testing, unnecessary treatment, and possible adverse e ects; possible stigma associated with a tuberculosis or MDR-TB diagnosis; and the chance that a falsepositive may halt further diagnostic evaluation. • False-negative (FN): increased risk of morbidity and mortality and delayed treatment initiation for patients. We were interested in the following roles for testing. Index test used as an initial test replacing usual practice (including conventional microscopy, culture or histopathology) for the diagnosis of extrapulmonary tuberculosis in adults with presumptive extrapulmonary tuberculosis (WHO Consolidated Guidelines (Module 3) 2020). An initial test does not mean that other tests will follow. Index test used as an initial test replacing culture and phenotypic DST for the diagnosis of rifampicin-resistant tuberculosis in adults with presumptive extrapulmonary tuberculosis (WHO Consolidated Guidelines (Module 3) 2020). As mentioned, in high MDR-TB settings the presence of rifampicin resistance alone may serve as a proxy for MDR-TB. Xpert Ultra and Xpert MTB/RIF do not eliminate the need for subsequent culture and phenotypic DST, which are required to monitor treatment progress and to detect resistance to drugs other than rifampicin. For a comprehensive review of new tests not yet in widespread use, we refer the reader to Branigan 2019; Lewinsohn 2017; Unitaid 2017. Smear microscopy (light microscopy (Ziehl-Neelsen), fluorescence microscopy, or light-emitting diode (LED) fluorescence microscopy) is the examination of smears for acid-fast bacilli (tuberculosis bacteria) under a microscope. Around 5000 to 10,000 organisms per mL must be present in the specimen for tuberculosis bacteria to be visible by microscopy (American Thoracic Society 2000) . For extrapulmonary tuberculosis, microscopy can be performed in fluid or tissue specimens from sites of disease involvement, for example, in cerebrospinal fluid (CSF) in presumptive tuberculous meningitis or in lymph node tissue in presumptive lymph node tuberculosis. For most extrapulmonary sites, because there are usually few organisms, the sensitivity of smear microscopy is generally low. Ranges from studies, some with selected cases, are quoted here: 0% to 10% in pleural fluid; 14% to 39% in pleural tissue; 2% to 30% in CSF; < 5% in peritoneal fluid; and 0% to 42% in pericardial fluid. In contrast, the specificity of smear microscopy tends to be quite high, as can be seen in pulmonary tuberculosis (≥ 90%) (Kilpatrick 1986; Lewinsohn 2017). Mycobacterial culture is a method used to grow bacteria on nutrient-rich media. In comparison with microscopy, a positive culture requires only around 100 organisms per mL and therefore can detect lower numbers of tuberculosis bacteria (American Thoracic Society 2000) . Additionally, culture is essential for species identification and DST. However, culture takes several weeks and requires a highly-equipped laboratory. Culture has reduced sensitivity in paucibacillary disease (reference standards have included culture from a di erent specimen, such as sputum, smear microscopy, NAATs, presence of granulomatous inflammation, clinical criteria, imaging studies, and response to anti-tuberculosis therapy, done alone or in various combinations): CSF 45% to 70%; pleural fluid 23% to 58%; urine 80% to 90%; peritoneal tuberculosis 45% to 69%; pericardial tuberculosis 50% to 65% (Lewinsohn 2017); lymph node tuberculosis (excisional biopsy) 18% to 93%; and lymph node tuberculosis (fine-needle aspirate) 10% to 67% (Fontanilla 2011). Histological examination involves examination of tissue specimens under a microscope. Diagnosis of extrapulmonary tuberculosis by histological examination is based on finding acid-fast bacilli and granulomatous inflammation, frequently with caseous (cheese-like) necrosis (necrotizing granulomas). The sensitivity of histology has been reported to vary for di erent forms of extrapulmonary tuberculosis (reference standards have included smear microscopy, culture, NAATs, clinical criteria, and imaging studies, done alone or in various combinations): 59% to 88% for lymph node tuberculosis (excisional biopsy) (Fontanilla 2011); 69% to 97% in pleural tissue (closed pleural biopsy); 86% to 94% in urological tissue; 60% to 70% in endometrial curettage; 79% to 100% in peritoneal biopsy; and 73% to 100% in pericardial tissue (Lewinsohn 2017). Sensitivity has also been observed to vary for di erent diagnostic techniques. Diacon 2003 found thoracoscopy to be more sensitive (sensitivity of 100%) than closed-needle biopsy (sensitivity of 66%) for establishing a diagnosis of pleural tuberculosis (reference standards have included microscopy smear, culture, or presence of granulomatous inflammation with caseous necrosis). Specificity has been observed to be low because of the presence of granulomas in other diseases, both infectious and non-infectious (Lewinsohn 2017), although the presence of 'necrotizing' granulomatous inflammation increases specificity (Woodard 1982) . Histological examination carries the additional concern that invasive procedures that are complex and costly may be required to obtain the necessary specimens (Golden 2005). Cytopathological examination of fluid specimens (such as pleural and peritoneal fluid) may be performed, first to exclude cancer, and then to obtain material for additional analyses, such as measurement of levels of adenosine deaminase and free interferon-gamma (IFN-γ) and cell counts (Lewinsohn 2017; Wright 2009a) . Advantages of these tests include that they are rapid and simple and can be performed in most clinical laboratories (Dinnes 2007). In pleural, pericardial, and peritoneal fluid, a predominance of lymphocytes, especially in the absence of mesothelial cells, is highly suggestive of tuberculosis (Wright 2009a). However, in HIV-positive people, this pattern may not be observed (Wright 2009a) . Adenosine deaminase, an enzyme involved in purine metabolism, has been extensively studied for its potential role in the diagnosis of pleural tuberculosis, peritoneal tuberculosis, and tuberculous meningitis (Lewinsohn 2017). IFN-γ is released a er it is sensitized by T cells in response to specific M tuberculosis antigens. A recent review of the evidence using GRADE provides the following recommendations. • "...cell counts and chemistries be performed on amenable fluid specimens (including include pleural, cerebrospinal, ascitic, and joint fluid) collected from sites of suspected extrapulmonary TB (conditional recommendation, very low-quality evidence). • ...adenosine deaminase levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB, TB meningitis, peritoneal TB, or pericardial TB (conditional recommendation, low-quality evidence). • ...free IFN-γ levels be measured, rather than not measured, on fluid collected from patients with suspected pleural TB or peritoneal TB (conditional recommendation, low-quality evidence)" (Lewinsohn 2017). NAAT is a molecular technique that can detect small quantities of genetic material (DNA or RNA) from micro-organisms, such as M tuberculosis. The key advantage of NAATs is that they are rapid diagnostic tests, potentially providing results in a few hours. This is a particularly important feature of the test in life-threatening forms of extrapulmonary tuberculosis, such as tuberculous meningitis. A variety of molecular amplification methods are available, of which PCR is the most common. NAATs are available as commercial kits and in-house tests (based on a protocol developed in a laboratory) and are used routinely in high-income countries for tuberculosis detection. In-house PCR is widely used in low-income countries because these tests are less expensive than commercial kits. An older editorial summarizing three systematic reviews (140 studies) of commercial and in-house NAATs (other than Xpert MTB/RIF) for di erent forms of extrapulmonary tuberculosis found relatively low sensitivity and underscored concerns about the cost and feasibility of this technology in resource-limited areas (Pai 2008) . Similarly, another systematic review found that NAATs have relatively low sensitivity for extrapulmonary tuberculosis but high specificity (e.g. for tuberculous meningitis, for pleural TB), indicating that these tests cannot be used reliably to rule out tuberculosis (Dinnes 2007). A recent evidence synthesis reported sensitivities of 72% to 88% in lymph node tissue, 28% to 81% in pleural fluid, 90% in pleural tissue, and 31% to 56% in CSF. Specificity ranged from 90% to 100% (Lewinsohn 2017). Alternative molecular methods for DST include the commercial line-probe assays, GenoType MTBDRplus assay (MTBDRplus, Hain LifeScience, Nehren, Germany), and the Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan), which detect the presence of mutations associated with drug resistance to isoniazid and rifampicin (Nathavitharana 2017). MTBDRplus is the most widely studied line-probe assay. Advantages of line-probe assays are that they can provide a result for detection of tuberculosis and drug resistance in one to two days. Drawbacks are that lineprobe assays are expensive and need to be used in intermediate and central laboratories (Unitaid 2017). The WHO recommends that for persons with a sputum smear-positive specimen or a cultured tuberculosis isolate, commercial molecular line-probe assays may be used as the initial test instead of phenotypic To estimate the diagnostic accuracy of Xpert Ultra and Xpert MTB/ RIF for a) extrapulmonary tuberculosis by site of disease and b) rifampicin resistance, in adults with presumptive extrapulmonary tuberculosis. Presumptive tuberculosis refers to a patient who presents with symptoms or signs suggestive of tuberculosis. • To compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for a) extrapulmonary tuberculosis by site of disease, and b) rifampicin resistance. • To investigate the e ects of potential sources of heterogeneity on test accuracy across the included studies. For potential sources of heterogeneity, for extrapulmonary tuberculosis, we included smear status, HIV status, and prevalence of extrapulmonary tuberculosis. For cerebrospinal fluid (CSF), we considered the presence of a concentration step and specimen volume. For rifampicin resistance, we planned to assess the impact of the prevalence of rifampicin resistance on accuracy estimates, but we had insu icient data for this analysis. We included cross-sectional and cohort studies. In addition, we had planned to include randomized controlled trials that evaluated the use of the index(s) test on patient health outcomes, but that also reported sensitivity and specificity. Although the study design was a randomized trial for the purpose of determining the impact of the test on participant outcomes, the study design was a crosssectional study for the purpose of determining the diagnostic accuracy of the index tests in this review. However, we did not identify any randomized controlled trials. We used abstracts to identify published studies and included these when they met the inclusion criteria. We only included studies that reported data comparing the index test(s) to an acceptable reference standard from which we could extract true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) values. We excluded case-control studies and case reports. We included studies where at least 85% of the participants enrolled were adults aged 15 years or older with presumptive extrapulmonary tuberculosis from all settings and countries. Restricting the age group to adults di ers from the original review, where we also included children (Kohli 2018). We did this because children are now included in a separate Cochrane Review (Kay 2020). We excluded studies where we could not disaggregate data on adults from those in children and studies where we could not tell the age of the participants enrolled. We included non-respiratory specimens (such as CSF, pleural fluid, lymph node aspirate or tissue). We excluded sputum and other respiratory specimens, such as fluid obtained from bronchial alveolar lavage and tracheal aspiration. As we anticipated finding many studies, we set a bar to exclude smaller studies to reduce unnecessary work. We therefore required studies to provide data for at least five specimens for a given form of extrapulmonary tuberculosis included in the review. We excluded studies evaluating the use of Xpert Ultra and Xpert MTB/RIF to diagnose relapse of previously-treated extrapulmonary tuberculosis, so as to avoid the selection bias that may arise by limiting to a group that is already at elevated risk of extrapulmonary tuberculosis. We attempted to identify studies that included participants who were not taking anti-tuberculosis drugs or had taken anti-tuberculosis drugs for less than seven days. The index tests were Xpert Ultra and Xpert MTB/RIF. Index test results are automatically generated (i.e. there is a single threshold), and the user is provided with a printable test result as follows. • The target conditions were extrapulmonary tuberculosis and rifampicin resistance. We included eight common forms of extrapulmonary tuberculosis and considered subcategories of the target condition as separate diagnostic classifications (CDC 2018; Sandgren 2013; Sharma 2004) . • Tuberculous meningitis. • Pleural tuberculosis. • Lymph node tuberculosis. • Genitourinary tuberculosis. • Bone or joint tuberculosis. • Peritoneal tuberculosis. • Pericardial tuberculosis. • Disseminated tuberculosis. Table 1 lists the forms of extrapulmonary tuberculosis and specimens used for diagnosis in the review. We excluded less common forms, such as cutaneous tuberculosis, ocular tuberculosis, female genital tuberculosis, and tuberculosis of the breast, ear, and paranasal sinuses (Sharma 2004). We included two reference standards. • Solid or liquid mycobacterial culture. In contrast to culture, a composite reference standard that includes culture, other tests, and clinical characteristics may correctly classify index test results as TPs (instead of as FPs with respect to culture), especially in people with paucibacillary disease in whom culture may be negative. However, because of the uncertainties that surround a clinical diagnosis of tuberculosis and, in some instances, the conditional dependence of the index tests and other tests in the composite reference standard (for example, for most of these tests, detection of tuberculosis depends on bacillary load), a reference standard that uses additional tests and clinical characteristics (in culture-negative people) may incorrectly classify people without tuberculosis as having tuberculosis (Naaktgeboren 2013). An additional challenge with including a composite reference standard is that the definition of the composite reference standard may vary across studies, making it di icult to interpret the accuracy estimates. Thus both reference standards, culture and composite, are imperfect and may a ect accuracy estimates. In an attempt to improve the estimation of diagnostic accuracy, we applied a latent class meta-analysis model to the three most commonly studied forms of extrapulmonary tuberculosis. This approach provides the sensitivity and specificity of culture in addition to the accuracy of the index tests, thus adjusting for imperfect culture accuracy. The reference standard was culture-based DST using solid or liquid media or line-probe assays, as recommended by the WHO (WHO 2012; WHO Consolidated Guidelines (Module 3) 2020). We attempted to identify all relevant studies, regardless of language or publication status (published, unpublished, in press, or ongoing) . We monitored abstracts to see if these studies were published during the time we performed the review. We included only published studies in the review. For the original review, we searched the literature on 7 August 2017. For this review update, we searched the literature on 2 August 2019 and again on 28 January 2020, specifically for studies of Xpert Ultra (studies could include Xpert Ultra alone or both Xpert Ultra and Xpert MTB/RIF), using the search terms and strategy described in Appendix 1. We searched the following databases: • To identify other systematic reviews and meta-analyses, we performed an additional search on 28 May 2020 in MEDLINE (PubMed), Embase (OVID), and the Cochrane Library, applying filters for systematic reviews (www.sign.ac.uk/search-filters.html) to search terms for Xpert and tuberculosis. We reviewed reference lists of included articles and any relevant review articles identified through the above methods. We also contacted researchers at FIND and other experts in the field of tuberculosis diagnostics for information on ongoing and unpublished studies. We used Covidence to manage the selection of studies (Covidence 2017). Two review authors independently scrutinized titles and abstracts identified by electronic literature searching to identify potentially eligible studies. We selected any citation identified by either review author as potentially eligible for full-text review. The same review authors independently assessed full-text papers for study eligibility using predefined inclusion and exclusion criteria, and resolved any discrepancies by discussion. We recorded all studies excluded a er full-text assessment and their reasons for exclusion in Characteristics of excluded studies. We illustrated the study selection process in a PRISMA diagram (Moher 2009). Using a previously-developed form (Appendix 2), two review authors worked independently to extract data on the following characteristics. We classified country income status as either low-and middleincome or high-income, according to the World Bank List of Economies (World Bank 2020). We extracted TP, FP, FN, and TN values for the following specimens: CSF, pleural fluid and tissue, lymph node aspirate and tissue (the latter specimen acquired by surgical biopsy), bone or joint aspirate and tissue, urine, peritoneal fluid and tissue, pericardial fluid and tissue, and blood. We extracted these values for each of the specimen types separately. For example, we used one 2 × 2 table for lymph node aspirate, and another 2 × 2 table for lymph node tissue. In situations in which a participant contributed more than one specimen but of di erent types, we extracted data for all specimens. When a study included data for both raw specimens and concentrated sediment involving the same participants, we preferentially extracted data for raw specimens, except in the case of CSF, for which we extracted data for concentrated sediment as recommended by the WHO (WHO 2014). We extracted accuracy data according to the defined reference standards (see Reference standards). We did not encounter any situations in which a subset of participants in a study received the reference standard but others did not. Hence, there was no need to make corrections for verification bias in the statistical analysis (Begg 1983) . In most studies, the number of specimens was the same as the number of participants. However, in some studies, the number of specimens exceeded the number of participants or study authors reported only the number of specimens. In the previous review (Kohli 2018), we added post hoc a sensitivity analysis limiting inclusion to studies that used one specimen per participant. In this review, we performed a similar sensitivity analysis for Xpert Ultra. We contacted authors of primary studies for missing data or clarifications. We entered all data into Microso Excel 2014. We used the QUADAS-2 tool, tailored to this review, to assess the quality of the included studies (Appendix 3) (Whiting 2011). QUADAS-2 consists of four domains: patient selection, index test, reference standard, and flow and timing. We assessed all domains for risk of bias and the first three domains for concerns about applicability. Two review authors independently completed QUADAS-2 and resolved disagreements through discussion. We present the results of this quality assessment in text, tables, and graphs. We followed Cochrane policy, which states that "authors of primary studies will not extract data from their own study or studies. Instead, another author will extract these data, and check the interpretation against the study report and any available study registration details or protocol". We performed descriptive analyses of the characteristics of included studies using Stata 15 (Stata 2017), and we present key study characteristics in the Characteristics of included studies table. We used data reported in the TP, FP, FN, and TN format to calculate sensitivity and specificity estimates and 95% confidence intervals (CIs) for individual studies. We present individual study results graphically by plotting the estimates of sensitivity and specificity (and their 95% CIs) in forest plots and receiver operating characteristic (ROC) space using Review Manager 5 (RevMan 5) (RevMan 2014). When data were su icient, we performed meta-analyses to estimate pooled sensitivity and specificity and corresponding 95% credible interval (CrI, defined below) using an adaptation of the bivariate random-e ects approach of Reitsma 2005, which uses the exact binomial likelihood for the observed proportions (Chu 2006) . The bivariate random-e ects approach allowed us to calculate the pooled estimates of sensitivity and specificity while dealing with potential sources of variation caused by (1) imprecision of sensitivity and specificity estimates within individual studies; (2) correlation between sensitivity and specificity across studies; and (3) variation in sensitivity and specificity between studies. The model has a hierarchical structure, with the logit sensitivity in individual studies assumed to come from a common probability distribution the mean of which is the pooled logit sensitivity, and the standard deviation is the between-study standard deviation, and likewise for the specificity. This structure allows for borrowing strength across studies. In the absence of su icient studies, we simply present descriptive statistics. In addition, we determined predictive values at a pretest probability of 10%, a value suggested by the WHO. We performed separate analyses grouped by type of extrapulmonary specimen (e.g. CSF, pleural fluid, peritoneal fluid) rather than determine summary accuracy estimates for all forms of extrapulmonary tuberculosis combined, because we considered the former approach to be most clinically meaningful. In addition, we performed separate analyses by reference standard. We performed comparative meta-analyses by restricting the analyses to only those studies that made direct comparisons between Xpert Ultra and Xpert MTB/RIF within the same participants (Takwoingi 2013). We extracted the median and the 95% CrI for the di erence in the pooled sensitivities and the di erence in the pooled specificities, respectively, of Xpert Ultra versus Xpert MTB/RIF. We also calculated the probability that the di erence exceeds zero in each case. For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection of rifampicin resistance, we include participants who (1) were culture-positive; (2) had a valid culture-based DST or lineprobe assay (LPA) result; (3) were Xpert MTB/RIF or Xpert Ultra tuberculosis-positive; and (4) had a valid Xpert MTB/RIF or Xpert Ultra result for rifampicin resistance, detected or not detected (susceptible). • Sensitivity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance detected/phenotypic DST or LPA rifampicin-resistant. • Specificity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance not detected/phenotypic DST or LPA rifampicin-susceptible. For detection of rifampicin resistance, when a study included multiple types of specimens, we based our determination of Xpert Ultra and Xpert MTB/RIF and sensitivity and specificity on all available data in the study, including data for specimens that we did not include in the primary analyses for detection of extrapulmonary tuberculosis. For example, if a study provided data for several specimen types combined (e.g. all tissue specimens) and we could not disaggregate the data for a specific specimen type, we included Cochrane Database of Systematic Reviews all data (for all tissue specimens) in the analysis for rifampicin resistance detection. We did this because we did not expect the accuracy of Xpert Ultra or Xpert MTB/RIF for rifampicin resistance to vary by specimen type. We used the bivariate random-e ects model to estimate pooled sensitivity and specificity. We estimated all models using a Bayesian approach with lowinformation prior distributions using OpenBUGS so ware (Version 3.2.3) (Lunn 2009), along with R (R Core Team 2019). Under the Bayesian approach, all unknown parameters must be provided a prior distribution that defines the range of possible values of the parameter and the weight of each of those values, based on information external to the data. To allow observed data to dominate the final results, we chose to use low-information prior distributions. We defined prior distributions on the logodds scale over the pooled sensitivity and specificity parameters, their corresponding between-study standard deviations, and the correlation between the sensitivities and specificities across studies. For the pooled log odds of the sensitivity or the pooled log odds of the specificity, we used a normal prior distribution with mean 0 and a wide variance of 4 (or a precision of 0.25). This corresponds to a roughly uniform distribution over the pooled sensitivity and pooled specificity on the probability scale. For the between-study precision, we used a gamma distribution with a shape parameter of 2 and a rate parameter of 0.5. This corresponds to a 95% prior CrI for the between-study standard deviation in the log odds of sensitivity or the log odds of specificity ranging from roughly 0.29 to 1.44, corresponding to moderate to high values of between-study heterogeneity. Covariance terms followed a uniform prior distribution whose upper and lower limits were determined by the sensitivity of the two tests. The OpenBUGS model used appears in Appendix 4. It is known that meta-analysis models can be sensitive to the choice of prior distributions over between-study standard deviation parameters. We therefore carried out sensitivity analyses and considered alternative prior distributions that are less informative, allowing a wider range of possible values. To study the sensitivity of all results to the choice of prior distributions given above, we considered alternative prior distributions that were less informative, allowing a wider range of possible values. We increased the variance of the normal distributions over the pooled log odds of sensitivity or specificity to 100. We used a uniform prior distribution ranging from 0 to 3 over the between-study standard deviation on the log odds scale (see programme in Appendix 4). We noted no appreciable change in pooled accuracy parameters but found that the posterior CrIs and prediction intervals were slightly wider, as expected. We combined information from the prior distribution with the likelihood of the observed data, in accordance with Bayes' theorem, using the OpenBUGS programme, which provides a sample from the posterior distribution of each unknown parameter. We were particularly interested in the pooled sensitivity and specificity of Xpert and between-study variance in the sensitivity and specificity of Xpert on the log-odds scale. Using a sample from the posterior distribution, we calculated various descriptive statistics of interest. We estimated the median pooled sensitivity and specificity and their 95% CrI. The median or the 50% quantile is the value below which 50% of the posterior sample lies. We report the median because the posterior distributions of some parameters may be skewed and the median would be considered a better point estimate of the unknown parameter than the mean in such cases. The 95% CrI is the Bayesian equivalent of the classical (frequentist) 95% confidence interval (CI) (we will indicate 95% CI for individual study estimates and 95% CrI for pooled study estimates as appropriate). The 95% CrI may be interpreted as an interval that has a 95% probability of capturing the true value of the unknown parameter, given observed data and prior information. We prepared summary receiver operating characteristic (SROC) curves for each meta-analysis model, using the methods described in Harbord 2007. We also determined the predicted sensitivity and specificity of Xpert MTB RIF and Xpert Ultra and their 95% CrIs. Predicted values represent our best guess for sensitivity and specificity in a future study and will be close to the pooled estimates. However, their CrIs may be di erent. If there is no heterogeneity at all between studies, the CrI around the predicted estimate will be the same as the CrI around the pooled estimate. On the other hand, if considerable heterogeneity is observed between studies, the CrI around the predicted estimate will be much wider than the CI around the pooled estimate. In addition, we performed latent class analysis for three forms of extrapulmonary tuberculosis: tuberculous meningitis, pleural tuberculosis, and lymph node tuberculosis, using data from the two-by-two tables comparing the index test to culture as a reference standard. Latent class analysis is a statistical modelling technique that allows estimation of test accuracy in the absence of an adequate reference standard to define the presence or absence of disease (Van Smeden 2014). The latent class metaanalysis model expands the traditional meta-analysis model in two ways: (1) we added parameters for the sensitivity and specificity of culture; and (2) we added covariance terms to adjust for the dependence between the index test and culture among diseasepositive and disease-negative participants in each study. We used hierarchical prior distributions over the logit sensitivity and logit specificity of culture. In other words, we assumed that the logit sensitivities in the individual studies come from a common probability distribution whose mean is the pooled mean logit sensitivity of culture and whose standard deviation is the betweenstudy standard deviation. Likewise for the specificities. We used the same low-information prior distributions over the pooled logit mean and between-study standard deviation parameters as we had for the corresponding parameters for the index test. We used uniform prior distributions for covariance terms over their ranges, which are determined by the sensitivities and the specificities of the two tests in each study (see Appendix 4 for the OpenBUGS model). We found that we did not need to augment observed data with prior information from other sources for most models. However, in a post hoc analysis Xpert MTB/RIF in lymph node aspirate in which we suspected a systematic bias in the performance of culture, we used informative prior distributions over the specificity of culture (ranging from 99% to 100%) and the specificity of Xpert MTB/RIF (ranging from 98% to 100%) (see Appendix 4). We added the SROC plots of the latent class meta-analyses to the SROC plots resulting from the models in which culture was treated as a perfect test, so they could be compared. Cochrane Database of Systematic Reviews correct the biases in Xpert Ultra and Xpert MTB/RIF sensitivity and specificity resulting from treating culture as a perfect reference standard, which we detailed earlier in the section on the reference standard. The proportion of inconclusive (non-determinate) rate for detection of pulmonary tuberculosis is the number of tests classified as 'invalid ', 'error', or 'no . We reported these findings again in this review update. As we found very few inconclusive results reported, we excluded these results from the quantitative analysis. Initially, we investigated heterogeneity through visual examination of forest plots of sensitivities and specificities and through visual examination of the ROC space of the raw data. When data allowed, we evaluated potential sources of heterogeneity using subgroup analyses and bivariate meta-regression. We included the following covariates. • HIV status. • For tuberculous meningitis, concentration step used for preparing specimen (yes or no). • CSF specimen volume used for Xpert MTB/RIF or Xpert Ultra testing. We had planned to investigate smear status, history of tuberculosis, and whether WHO standard procedures for preparing tissue specimens were followed. However, we had insu icient data to do this. The impact of the prevalence of extrapulmonary tuberculosis on sensitivity and specificity is an important consideration. In a post hoc meta-regression analysis, for Xpert MTB/RIF we explored this question for CSF, pleural fluid, and lymph node aspirate. For Xpert Ultra we explored this question for CSF. We did not conduct other analyses, owing to an insu icient number of studies. For detection of rifampicin resistance, owing to a small number of studies, we could not assess the impact of prevalence of rifampicin resistance on accuracy estimates. Nontuberculous mycobacteria ( For Xpert Ultra testing in CSF, we performed sensitivity analyses to explore whether the overall findings were robust to potentially influential decisions. We did this by limiting inclusion in the metaanalysis to the following. • Studies that used consecutive or random selection of participants. • Studies in which the reference standard results were interpreted without knowledge of the index test results. • Studies that included only one specimen per participant. For Xpert Ultra, in CSF, we also planned to perform a sensitivity analysis by limiting studies to those that included only untreated participants. However, we were unable to confirm that studies met this criterion. We planned similar sensitivity analyses for pleural fluid and lymph node aspirate, but these analyses were not carried out owing to an insu icient number of studies. For all other specimen types, we had an insu icient number of studies for sensitivity analyses. For Xpert MTB/RIF, in the original review we performed sensitivity analyses by type of extrapulmonary specimen and found that for most analyses, the sensitivity analyses made little di erence to any of these findings (Kohli 2018). However, for Xpert MTB/RIF in CSF, in comparison with all studies, (sensitivity of 71.1% (60.9 to 80.4), and specificity of 98.0% (97.0 to 98.8)), studies that evaluated only one specimen per participant had lower pooled sensitivity at 63.5% (47.6 to 76.3) and lower pooled specificity at 96.1% (94.2 to 97.4). We did not perform a formal assessment of publication bias using methods such as funnel plots or regression tests because such techniques have not been helpful for diagnostic test accuracy studies (Macaskill 2010). We assessed the certainty of evidence using the GRADE approach for diagnostic studies (Balshem 2011; GRADEpro GDT 2015; Schünemann 2008; Schünemann 2016) . As recommended, we rated the certainty of evidence as either high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) based on five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the certainty of evidence started as high when there high-quality studies (cross-sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels).Two review authors discussed judgments and applied GRADE in the following way (Schünemann 2020a; Schünemann 2020b). • Assessment of risk of bias. We used QUADAS-2 to assess risk of bias. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews • Indirectness. We assessed indirectness in relation to the population (including disease spectrum), setting, interventions, and outcomes (accuracy measures). We also used prevalence as a guide to whether there was indirectness in the population. • Inconsistency. GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We carried out prespecified analyses to investigate potential sources of heterogeneity and downgraded when we could not explain inconsistency in the accuracy estimates. • Imprecision. We considered a precise estimate to be one that would allow a clinically meaningful decision. We considered the width of the CrI (or CI) and asked, "Would we make a di erent decision if the lower or upper boundary of the CrI (or CI) represented the truth?" In addition, we worked out projected ranges for TP, FN, TN, and FP for a given prevalence of tuberculosis and made judgements on imprecision from these calculations. • Publication bias. We rated publication bias as undetected (not serious) for several reasons: the comprehensiveness of the literature search and extensive outreach to tuberculosis researchers to identify studies; the presence only of studies that produced precise estimates of high accuracy despite small sample size; and our knowledge about studies that were conducted but not published. For the 'Summary of findings' tables for CSF and pleural fluid, we provide evidence using culture as the reference standard, which is considered the best reference standard for tuberculosis (Lewinsohn 2017). For lymph node aspirate, we provide evidence using a composite reference because, based on findings from the original review (Kohli 2018), we believe a composite reference standard is preferable for estimating accuracy. We identified and screened a total of 735 records for inclusion in this review update. Of these, we assessed 142 full-text papers against our inclusion criteria. We excluded 120 papers, mainly for the following reasons: study did not evaluate Xpert Ultra (n = 54); could not extract 2 x 2 values (n = 14); inappropriate reference standard (n = 13); could not extract data by specimen type (n = 12); did not include extrapulmonary specimen (n = 10): duplicate data (n = 4); case-control study (n = 4); index test other than Xpert MTB/ RIF or Xpert Ultra (n = 3); study included children (n = 2); screening study (n = 2); case report (n = 1); and fewer than five specimens for a given specimen type (n = 1). From our previous review, we included 47 studies. Thus, we included 69 unique studies that met the inclusion criteria in this review update. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Three studies (4%) had high concern because participants were evaluated exclusively as inpatients at a tertiary care centre (Che 2017; Du 2015; Gu 2015); and 52 (75%) studies had unclear or high concern because we could not tell the clinical setting or a high percentage of participants had received prior testing for tuberculosis (Antel 2020). In the index test domain, we thought that all studies had low risk of bias because the results of the index tests (Xpert Ultra and Xpert MTB/RIF) are automatically generated, the user is provided with printable test results, and the test threshold is prespecified. Regarding applicability, with respect to Xpert Ultra, we thought that 9/11 studies (82%) had low risk of bias (Antel 2020; Bahr 2017; Cresswell 2020; Donovan 2020; Meldau 2019; Perez-Risco 2018; Sun 2019; Wang 2019; Wang 2020) and 2/11 studies (18%) had high risk of bias because the index test was not performed according to WHO standard operating procedures (Chin 2019; Wu 2019). With respect to Xpert MTB/RIF, we thought that 45/67 studies (67%) had low concern because at least 75% of the specimen types in these studies were processed according to WHO recommendations; 17/67 studies (25%) had high concern because fewer than 50% of the specimen types in these studies were processed according to WHO recommendations ( Regarding applicability of the reference standard, we thought that 53 studies (77%) had low concern because these studies performed a test to identify M tuberculosis species (speciation) and 16 studies (23%) had unclear concern because we could not tell whether the study performed speciation ( In the flow and timing domain, we considered almost all studies to have low risk of bias, noting that all participants were accounted for in the analysis. One study included fewer than 50% of eligible participants in the analysis (Trajman 2014). Figure 5 and Figure 6 show risk-of-bias and applicability concerns for each of the five studies included for rifampicin resistance detection. Cochrane Database of Systematic Reviews In the patient selection domain, we thought that four studies (80%) had low risk of bias (Chin 2019; Sun 2019; Wang 2019; Wang 2020) and one study (20%) had unclear risk of bias as the manner of patient selection was unclear (Wu 2019). We thought that one study (20%) had low concern because participants were evaluated exclusively as inpatients at a tertiary care centre (Chin 2019) and four studies (80%) had unclear concern because we could not tell the details of the clinical setting (Sun 2019; Wang 2019; Wang 2020; Wu 2019). In the index test domain, we thought that all studies had low risk of bias because the results of the index tests are automatically generated, the user is provided with printable test results, and the test threshold is prespecified. For applicability, with respect to Xpert Ultra, we thought that three studies (60%) had low concern because at least 75% of the specimen types in these studies were processed according to WHO recommendations (Sun 2019; Wang 2019; Wang 2020); two studies (40%) had high concern because fewer than 50% of the specimen types in these studies were processed according to WHO recommendations (Chin 2019; Wu 2019). In the reference standard domain, two studies (40%) had low risk of bias because results of the reference standard were interpreted without knowledge of results of the index test and only non-sterile specimens were decontaminated (Chin 2019; Wu 2019). Three studies (60%) had unclear risk of bias as it was unclear whether blinding of the reference standard was performed (Sun 2019; Wang 2019; Wang 2020). For applicability of the reference standard, we thought that all studies had low concern because detection of rifampicin resistance occurs only when the M tuberculosis target is present within the specimen. In the flow and timing domain, we considered all studies to have low risk of bias, noting that all participants were accounted for in the analysis. Trusted evidence. Informed decisions. Better health. The 69 studies were conducted in 28 di erent countries. Most of the studies were conducted in China (n = 10), India (n = 13), South Africa (n = 10), and Uganda (n = 6). Seven studies exclusively or mainly included HIV-positive participants (Ablanedo-Terrazas 2014; Azevedo 2018; Bahr 2015; Bahr 2017; Cresswell 2020; Feasey 2013; Van Rie 2013). Most studies performed the index tests and culture on the same specimen type, except for one study in which Xpert MTB/RIF was performed on blood and culture was performed on sputum (Feasey 2013). Most studies did not report the exact number of cultures used to confirm a diagnosis of tuberculosis, but it is likely that many studies used a single culture. We present key characteristics of the included studies in the Characteristics of included studies table. Xpert Ultra: of the 11 studies, the number evaluating di erent specimens was as follows: tuberculous meningitis (CSF) six studies; pleural tuberculosis (pleural fluid) four studies; lymph node tuberculosis (lymph node aspirate) one study; genitourinary tuberculosis (urine) one study; bone or joint tuberculosis (bone or joint aspirate) two studies; and peritoneal tuberculosis (peritoneal fluid) one study. Xpert MTB/RIF: of the 67 studies, the number of studies evaluating di erent specimens was as follows: tuberculous meningitis (CSF) 33 studies; pleural tuberculosis (fluid) 27 studies; lymph node tuberculosis (aspirate 15 studies, biopsy 11 studies); genitourinary tuberculosis (urine) 15 studies; bone or joint tuberculosis (aspirate 12 studies, tissue 3 studies); peritoneal tuberculosis (fluid 17 studies, tissue 1 study); pericardial tuberculosis (fluid 14 studies, tissue 2 studies); and disseminated tuberculosis (blood 2 studies). Several studies included more than one type of specimen. In CSF, Xpert Ultra pooled sensitivity and specificity against a composite reference standard were 62.7% (45.7 to 77.0) and 99.1% (96.6 to 99.9), (4 studies; 496 participants); Table 2, Figure 7 . We had insu icient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in CSF. Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Figure 9 ; Figure 10 . For CSF, the di erence between the sensitivities of Xpert Ultra and Xpert MTB/RIF was 26.2% (9.1 to 44.4). We estimated the probability that the pooled sensitivity of Xpert Ultra exceeds that of Xpert MTB/RIF was 0.997. The di erence between the specificities of Xpert Ultra and Xpert MTB/RIF was −5.6% (−12.9 to −0.1). We estimated the probability that the pooled specificity of Xpert Ultra was less than that of Xpert MTB/RIF was 0.978; Table 4 . shaded square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region. For Xpert Ultra, we found lower sensitivity in settings with higher tuberculosis prevalence (threshold 30%) than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 88.3% (68.3 to 97.0) versus 90.8% (77.3 to 96.9). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 88.0% (64.3 to 97.9) versus 91.9% (82.5 to 96.6) . In both analyses, the 95% Crls overlapped; Table 6 . Similarly, for Xpert MTB/RIF, we found lower sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity of 67.0% (49.0 to 81.5) versus 72.0% (62.4 to 81.2). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 94.1% (86.8 to 97.9) versus 97.3% (95.9 to 98.3). In both analyses, the 95% Crls overlapped; Table 6 . When we repeated the analysis at lower tuberculosis prevalence (threshold 10%), in the case of specificity, accuracy in the two groups was significantly di erent (probability of specificity being lower in the high tuberculosis prevalence group = 0.999); Table 6 . Overall, the sensitivity analyses made little di erence to the findings; Table 7 Inconclusive Xpert Ultra and Xpert MTB/RIF results None of the studies evaluating Xpert Ultra for tuberculous meningitis reported this information. We previously reported that for CSF, of 2096 tests performed, the pooled proportion of inconclusive Xpert MTB/RIF results was 0.9% (95% CrI 0.3 to 1.9) (Kohli 2018). Xpert Ultra Four studies evaluated Xpert Ultra in pleural fluid with respect to culture (Perez-Risco 2018; Wang 2019; Wang 2020; Wu 2019). Xpert Ultra sensitivity ranged from 48% to 84% and specificity ranged from 65% to 100%; Figure 12 . Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews In pleural fluid, Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) and 87.0% (63.1 to 97.9), (4 studies; 398 participants, 158 (39.7%) with tuberculosis); Table 2 ; Appendix 8. Two studies evaluated Xpert Ultra in pleural fluid with respect to a composite reference standard (Meldau 2019; Wang 2019); Figure 12 ; Appendix 8. Sensitivity ranged from 38% to 61%, and specificity ranged from 96% to 99%. We could not explain the variability in the sensitivity estimates and did not perform a meta-analysis. We had insu icient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in pleural fluid. Xpert MTB/RIF sensitivity ranged from 0% to 100% and specificity ranged from 82% to 100% ( Figure 12 ). Three studies (Christopher 2013; Hillemann 2011; Iram 2015) did not contribute data to the meta-analysis because sensitivity was not estimable. In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) and 98.9% (97.6 to 99.7) (25 studies; 3065 participants, 644 (21.0%) with tuberculosis); Table 2 ; Appendix 8. In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity against a composite reference standard were 18.9% (11.5 to 27.9) and 99.3% (98.1 to 99.8), (10 studies; 1024 participants) Table 2; Figure 12 . Based on the latent class meta-analysis model, Xpert We had insu icient data for this analysis. For Xpert Ultra, we had insu icient data for this analysis. For Xpert MTB/RIF, we found higher sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 20.7% (11.2 to 33.7) versus 15.5% (6.5 to 30.1). We found similar specificity in settings with higher tuberculosis prevalence and in those with lower tuberculosis prevalence: pooled specificity of 99.6% (97.9 to 99.9) versus 99.0% (96.9 to 99.8). In both analyses, the 95% Crls overlapped; Table 6 . For Xpert Ultra, we had insu icient data for these analyses. Of the total 1013 tests performed, the percentage of inconclusive Xpert Ultra results was 0.3%. Only one study reported this information (Wang 2019). We previously reported that for pleural fluid, of 1416 tests performed the pooled proportion of inconclusive Xpert MTB/RIF results was 1.2% (95% CrI 0.4 to 2.6) (Kohli 2018). Cochrane Database of Systematic Reviews Xpert Ultra We did not identify any studies evaluating Xpert Ultra in pleural tissue against culture. We did not identify any studies evaluating Xpert Ultra in pleural tissue against a composite reference standard. Four studies evaluated Xpert MTB/RIF in pleural tissue with respect to culture (Christopher 2013; Du 2015; Ozkutuk 2014; Suzana 2016). Xpert MTB/RIF sensitivity ranged from 0% to 85% and specificity ranged from 97% to 100%; Figure 12 . One study reported zero tuberculosis cases (Suzana 2016). We did not perform a metaanalysis. In pleural tissue, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 0% (0 to 23) and 98% (87 to 100) (1 study; 55 participants; Christopher 2013); Figure 12 . Xpert Ultra In lymph node aspirates, Xpert Ultra sensitivity and specificity against culture were 78% (40 to 97) and 78% (66 to 87), (1 study; 73 participants; 9 (12.3%) with tuberculosis; Antel 2020); Figure 13 . Cochrane Database of Systematic Reviews In lymph node aspirates, Xpert Ultra sensitivity and specificity against a composite reference standard were 70% (51 to 85) and 100% (92 to 100), (1 study; 73 participants; 9 (12.3%) with tuberculosis; Antel 2020); Figure 13 . Of note, with a composite reference standard, specificity was higher (100%) than that observed when using culture as the reference standard (78%). We had insu icient data to obtain robust parameter estimates using the latent class model for Xpert Ultra in lymph node aspirate. Fi een studies evaluated Xpert MTB/RIF in lymph node aspirates with for culture ( Xpert MTB/RIF sensitivity ranged from 59% to 100% and specificity from 57% to 100%; Figure 13 . Xpert MTB/RIF specificity in lymph node aspirates was considerably more heterogeneous than in CSF and pleural fluid. The variability in Xpert MTB/RIF specificity in lymph node aspirates was unexpected and may be the result of a systematic, unexplained bias in some studies. One study did not contribute data to the metaanalysis because sensitivity was not estimable (Kim 2015a). In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and specificity against culture were 88.9% (82.7 to 93.6) and 86.2% (78.0 to 92.3) (14 studies; 1588 participants, 627 (39.5%) with tuberculosis); Table 2 . In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and specificity against a composite reference standard were 81.6% (61.9 to 93.3) and 96.4% (91.3 to 98.6), (4 studies; 679 participants); Table 2 ; Figure 13 . Of note, with a composite reference standard, specificity was less variable and pooled specificity higher than that observed when using culture as the reference standard (86.0%). Based on the latent class meta-analysis model, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) in lymph node aspirate were 91.3% (84.9 to 96.3) and 99.5% (99.1 to 99.7) (14 studies; 1588 participants); Table 3 . Xpert MTB/RIF pooled sensitivity and pooled specificity were higher than when culture was treated as having perfect accuracy, with pooled sensitivity of 88.9% (82.7 to 93.6) and pooled specificity of 86.2% (78.0 to 92.3). The pooled sensitivity of culture at 84.9% (74.0 to 92.8) was estimated to be lower than 100%. The pooled specificity of culture was estimated to be 98.8% (97.7 to 99.4); Table 3 . The latent class meta-analysis resulted in high precision in the specificity of Xpert MTB/RIF across studies. This was the result of adjustments for the imperfect and heterogeneous accuracy of culture across studies. We had insu icient data for this analysis. For Xpert Ultra, we had insu icient data for this analysis. For Xpert MTB/RIF, we found higher sensitivity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled sensitivity (95% CrI) of 93.1% (88.9 to 96.3) versus 72.2% (64.9 to 87.2). We found lower specificity in settings with higher tuberculosis prevalence than in those with lower tuberculosis prevalence: pooled specificity of 83.2% (69.5 to 92.1) versus 90.0% (78.3 to 95.9). In the case of sensitivity, accuracy in the two groups was significantly di erent (probability of sensitivity being lower in the high tuberculosis prevalence group = 0.999); Table 6 . For Xpert Ultra, we had insu icient data for these analyses. None of the studies reported this information. We previously reported that for lymph node aspirates, in the 1134 tests performed, the pooled proportion of inconclusive Xpert MTB/ RIF results was 1.0% (95% CrI 0.4 to 2.0) (Kohli 2018). Xpert Ultra In lymph node biopsies, Xpert Ultra sensitivity and specificity against culture were 90% (55 to 100) and 87% (77 to 94) (Antel 2020) and 100% (75 to 100) and 38% (22 to In lymph node biopsies, Xpert Ultra sensitivity and specificity against a composite reference standard were 73% (50 to 89) and 96% (88 to 100) (Antel 2020), (1 study; 81 participants); Figure Xpert MTB/RIF sensitivity ranged from 50% to 100% and specificity ranged from 0% to 100%; Figure 14 . We could not explain the heterogeneity in accuracy estimates by study quality, small numbers, or other factors. In lymph node biopsies, Xpert MTB/RIF pooled sensitivity and specificity against culture were 82.4% (73.5 to 89.7) and 80.3% (60.3 to 91.5), (11 studies; 786 participants, 220 (28.0%) with tuberculosis); Table 2 . In lymph node biopsies, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (27 to 40) and 85% (73 to 93) (Sarfaraz 2018) and 76% (50 to 93) and specificity of 100% (66 to 100) (Zeka 2011) (2 studies; 288 participants); Figure 14 . Xpert Ultra In urine, Xpert Ultra sensitivity and specificity against culture were 100% (74 to 100) and 100% (74 to 100), (1 study; 24 participants, 12 (50%) with tuberculosis) (Perez-Risco 2018); Figure 15 . Cochrane Database of Systematic Reviews The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: falsenegative; FP: false-positive; TN: true-negative; TP: true-positive. We did not identify any studies that evaluated Xpert Ultra in urine against a composite reference standard. Zmak 2013). Xpert MTB/RIF sensitivity ranged from 0% to 100% (sensitivity of 0% was reported by Zeka 2011 that had only one culture positive, which was Xpert negative) and specificity from 33% to 100% ( Figure 15 ). Six studies (Blaich 2014; Causse 2011; Malbruny 2011; Nataraj 2016; Sharma 2014; Zmak 2013) did not contribute data to the meta-analysis because either sensitivity or specificity was not estimable. In urine, Xpert MTB/RIF pooled sensitivity and specificity against culture were 85.9% (71.4 to 94.3) and 98.1% (93.1 to 99.7) (9 studies; 943 participants, 72 (7.6%) with tuberculosis); Table 2 . In urine, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (1 to 91) and 100% (92 to 100) (Sharma 2014), and 41% (33 to 50 ) and 100% (99 to 100) (Chen 2019) (2 studies; 463 participants); Figure 15 . Xpert Ultra In bone or joint aspirate, Xpert Ultra sensitivity and specificity against culture were 88% (47 to 100) (specificity was not estimable) (Perez-Risco 2018), and 96% (87 to 100) and 97% (85 to 100) (Sun 2019) (2 studies; 94 participants, 60 (63.8%) with tuberculosis); Appendix 9. In bone or joint aspirate, Xpert Ultra sensitivity and specificity against a composite reference standard were 96% (91 to 99) and 97% (85 to 100), (1 study; 145 participants; Sun 2019); Appendix 9. Cochrane Database of Systematic Reviews sensitivity ranged from 96% to 100% and specificity ranged from 53% to 100%; Appendix 9. In bone or joint aspirate, Xpert MTB/RIF pooled sensitivity and specificity against culture were 97.9% (93.1 to 99.6) and 97.4% (80.2 to 100.0); (6 studies; 471 participants, 110 (23.4%) with tuberculosis); Table 2 Composite reference standard In bone or joint aspirate, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 82% (69 to 91) and 100% (69 to 100) (Gu 2015), and 94% (87 to 97) and 100% (90 to 100) (Sun 2019); (2 studies; 205 participants); Appendix 9. Xpert Ultra We did not identify any studies that evaluated Xpert Ultra in tissue for bone or joint tuberculosis against culture. We did not identify any studies that evaluated Xpert Ultra in tissue for bone or joint tuberculosis against a composite reference standard. Three studies evaluated Xpert MTB/RIF in bone or joint tissue against culture. Xpert MTB/RIF sensitivity ranged from 50% to 100% and specificity ranged from 94% to 100% (Appendix 9). In bone or joint tissue, Xpert MTB/RIF sensitivity and specificity (95% CI) against culture were 100% (3 to 100) and 100% (48 to 100) (Malbruny 2011), 100% (3 to 100) and 100% (40 to 100) (Ozkutuk 2014), and 50% (1 to 99) and 94% (71 to 100) (Peñata 2016); (3 studies; 30 participants, 4 (13.3%) with tuberculosis). We did not identify any studies that evaluated Xpert MTB/RIF in tissue for bone or joint tuberculosis against a composite reference standard. Xpert Ultra In peritoneal fluid, Xpert Ultra sensitivity against culture was 33% (1 to 91) and specificity was not estimable (Perez-Risco 2018) (1 study; 3 participants); Appendix 10. We did not identify any studies that evaluated Xpert Ultra in peritoneal fluid against a composite reference standard. In individual studies, Xpert MTB/RIF sensitivity ranged from 33% to 100% and specificity ranged from 90% to 100%; Figure 16 ; Appendix 10. Trusted evidence. Informed decisions. Better health. In peritoneal fluid, Xpert MTB/RIF pooled sensitivity and specificity against culture were 59.1% (42.1 to 76.2) and 97.6% (95.4 to 98.9), (13 studies; 580 participants, 94 (16.2%) with tuberculosis); Table 2 . We did not identify any studies that evaluated Xpert MTB/RIF in peritoneal fluid against a composite reference standard. Xpert Ultra We did not identify any studies that evaluated Xpert Ultra in peritoneal tissue against culture. We did not identify any studies that evaluated Xpert Ultra in peritoneal tissue against a composite reference standard. In peritoneal tissue, Xpert MTB/RIF sensitivity and specificity against culture were 50% (7 to 93) and 92% (73 to 99) (1 study; 28 participants; Bera 2015); Appendix 10. We did not identify any studies that evaluated Xpert MTB/RIF in peritoneal tissue against a composite reference standard. Xpert Ultra We did not identify any studies that evaluated Xpert Ultra in pericardial fluid against culture. We did not identify any studies that evaluated Xpert Ultra in pericardial fluid against a composite reference standard. Table 2 ; Appendix 10. We did not identify any studies that evaluated Xpert MTB/RIF in pericardial fluid against a composite reference standard. Xpert Ultra We did not identify any studies that evaluated Xpert Ultra in blood against culture. We did not identify any studies that evaluated Xpert Ultra in blood against a composite reference standard. Two studies evaluated Xpert MTB/RIF in blood against culture (Feasey 2013; Zmak 2013). However, only one of these studies reported tuberculosis culture-positives. Xpert MTB/RIF sensitivity and specificity against culture were 56% (21 to 86) and 94% (85 to 98) (1 study; 74 participants, 9 (12.2%) with tuberculosis (Feasey 2013)); Appendix 10. We did not identify any studies that evaluated Xpert MTB/RIF in blood against a composite reference standard. For Xpert Ultra, two studies provided data on a variety of NTMs that grew from the specimens tested to look for evidence of cross-reactivity. Donovan 2020 assessed Xpert Ultra specificity in CSF from more than 100 participants with nontuberculous meningitis and found zero positive Xpert Ultra results in those with a probable or possible diagnosis of tuberculous meningitis and in any participant with a confirmed diagnosis of nontuberculous meningitis. Perez-Risco 2018 assessed Xpert Ultra specificity using 20 culture-positive NTM specimens (covering a total of 18 species) and found that Xpert Ultra was negative for all specimens. For Xpert MTB/RIF, we previously reported that in 10 studies involving 6975 specimens with 141 NTMs, Xpert MTB/RIF was negative in all specimens (Kohli 2018). Five studies evaluated Xpert Ultra for detection of rifampicin resistance. Xpert Ultra sensitivity estimates varied from 50% to 100%; specificity varied from 93% to 100%; Figure 17 . One study reported zero participants with rifampicin resistance and thus sensitivity was not estimable (Chin 2019 Figure 17 . Of the total 391 tests positive by Xpert Ultra, the proportion of indeterminate Xpert Ultra results for RIF resistance was 36.1%. All of these indeterminate results were Xpert Ultra trace-positive. We previously reported that for rifampicin resistance testing, of 1003 tests performed, the pooled proportion of indeterminate Xpert MTB/RIF results was 2.6% (95% CrI 1.4 to 4.3) (Kohli 2018). Cochrane Database of Systematic Reviews years and older. We also include a composite reference standard in addition to a culture reference standard, and have stratified all analyses by type of reference standard. Major findings from our review include the following. • Xpert Ultra sensitivity for tuberculosis varied across di erent types of specimens (from 75.0% in pleural fluid to 89.4% in cerebrospinal fluid); (Summary of findings 1) Results of these studies indicate that in theory, for a population of 1000 people where 100 have tuberculosis meningitis on culture, 168 would be Xpert Ultra-positive: of these, 79 (47%) would not have tuberculosis (false-positives); and 832 would be Xpert Ultra-negative: of these, 11 (1%) would have tuberculosis (falsenegatives). Results of these studies indicate that in theory, for a population of 1000 people where 100 have tuberculosis meningitis on culture, 99 would be Xpert MTB/RIF-positive: of these, 28 (28%) would not have tuberculosis (false-positives); and 901 would be Xpert MTB/ RIF-negative: of these, 29 (3%) would have tuberculosis (falsenegatives). Rapid diagnosis of tuberculous meningitis is critical so that lifesaving treatment can be started promptly. Around 50% of those a ected die or experience disabling consequences (Thwaites 2013). Xpert Ultra was designed to improve tuberculosis detection, in particular in people with paucibacillary disease. The limit of detection for MTB is lower with Xpert Ultra (16 bacterial colony-forming units (cfu) per mL) than with Xpert MTB/RIF (131 cfu per mL) (Chakravorty 2017). In studies that compared Xpert Ultra and Xpert MTB/RIF in the same participants, we found Xpert Ultra to have higher pooled sensitivity (89.0%) than Xpert MTB/RIF (62.2%), and lower pooled specificity (91.0%) than Xpert MTB/RIF (96.8%) for tuberculous meningitis. In addition, in subgroup analyses we found slightly higher Xpert Ultra accuracy in studies that concentrated the cerebrospinal fluid (CSF): pooled sensitivity of 90.5% in concentrated specimens versus 88.4% in unconcentrated specimens; and pooled specificity of 91.9% in concentrated specimens versus 88.6% in unconcentrated specimens. We note that subgroup findings should be interpreted with caution, as there were only three studies and a small number of tuberculous meningitis cases included. The Tuberculous Meningitis International Research Consortium has recommended increasing the volume of CSF collected for diagnosis followed by centrifugation as a way of improving Xpert MTB/RIF assay sensitivity (Bahr 2016); however, we did not have su icient data to investigate CSF collection volume. Increased Xpert MTB/RIF sensitivity in HIV-positive people compared with HIV-negative people has been reported, with the increased bacterial burden in tuberculosis and HIV co-infection proposed as the reason (Patel 2013). We had limited data to investigate this for Xpert Ultra as we identified only two studies in HIV-positive people, with sensitivities of 90% (Bahr 2017) and 89% (Cresswell 2020). (Summary of findings 2) Results of these studies indicate that in theory, for a population of 1000 people where 100 have pleural tuberculosis on culture, 192 would be Xpert Ultra-positive: of these, 117 (61%) would not have tuberculosis (false-positives); and 808 would be Xpert Ultra-negative: of these, 25 (3%) would have tuberculosis (falsenegatives). Results of these studies indicate that in theory, for a population of 1000 people where 100 have pleural tuberculosis on culture, 60 would be Xpert MTB/RIF-positive: of these, 10 (17%) would not have tuberculosis (false-positives); and 940 would be Xpert MTB/ RIF-negative: of these, 50 (5%) would have tuberculosis (falsenegatives). With the bivariate model, we found Xpert Ultra to have higher pooled sensitivity (75.0%) than Xpert MTB/RIF (49.6%) and lower pooled specificity (87.0%) than Xpert MTB/RIF (98.7%) in pleural fluid against a culture reference standard, between-study comparison. Based on the latent class meta-analysis model, Xpert Ultra pooled sensitivity was comparable (76.0%) and specificity higher (99.5%) than what was obtained when culture was treated Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews as having perfect accuracy. Xpert Ultra pooled sensitivity in pleural fluid was lower than that of CSF. One reason for the lower sensitivity of Xpert Ultra in pleural fluid could be the paucibacillary nature of pleural tuberculosis. Other possible reasons are contamination of blood or the presence of certain polymerase chain reaction (PCR) inhibitors in the pleural fluid (Pai 2004; Woods 2001) . However, Theron and colleagues found that extrapulmonary specimens showed less evidence of PCR inhibition than pulmonary specimens, with bacterial load being more important for a positive Xpert MTB/ RIF result (Theron 2014b). Given that false-negative results were common (low sensitivity), a negative Xpert Ultra or Xpert MTB/RIF result may not be relied on to exclude tuberculosis. Results of these studies indicate that in theory, for a population of 1000 people where 100 have lymph node tuberculosis verified by a composite reference standard, 70 would be Xpert Ultra-positive: of these, 0 (0%) would not have tuberculosis (false-positives); and 930 would be Xpert Ultra-negative: of these, 30 (3%) would have tuberculosis (false-negatives). Results of these studies indicate that in theory, for a population of 1000 people where 100 have lymph node tuberculosis verified by a composite reference standard, 118 would be Xpert MTB/RIFpositive: of these 37 (31%) would not have tuberculosis (falsepositives); and 882 would be Xpert MTB/RIF-negative: of these 19 (2%) would have tuberculosis (false-negatives). Regarding Xpert testing for lymph node aspirate, it important to point out that although tissue biopsy provides material for histological examination which may be of substantial diagnostic value, a fluid specimen may be collected more easily. In addition, fine-needle aspiration of lymph nodes is well suited for use in resource-limited settings because the procedure is simple, easy to learn, minimally invasive, and inexpensive (Wright 2009b). Thus clinicians may want to consider fine-needle aspiration of lymph nodes before surgical biopsy. In our review, using a standard bivariate meta-analysis model, Xpert MTB/RIF pooled specificity (defined by culture) in lymph node aspirate was 86.0%, whereas with a composite reference standard pooled specificity increased to 95.9%. Using a latent class meta-analysis model with informative priors, Xpert MTB/RIF pooled specificity increased to 99.5%. In previous meta-analyses, Xpert MTB/RIF specificity for lymph node tuberculosis (aspirate and tissue) against culture as a reference standard was 94% (Denkinger 2014), 93% (Maynard-Smith 2014), and 92% (Penz 2015). See Table 8 . Using a composite reference standard (defined by the primary study authors), Denkinger 2014 found increased Xpert MTB/RIF specificity of 99% for lymph node tuberculosis (5 studies, 728 specimens). Thus, it appears that accuracy results depend in part on the choice of reference standard. Regarding the use of a composite reference standard, owing to di ering definitions and di iculty in interpreting them, there is a risk of bias (Schiller 2016) (see section Strengths and weaknesses of the review). We considered several reasons why the specificity of Xpert Ultra (78%) and Xpert MTB/RIF (86.0%) in lymph node aspirate against culture would be lower than in other extrapulmonary specimens. Although not always reported, studies may have included participants receiving tuberculosis treatment. We previously reported that in a sensitivity analysis limiting inclusion to studies that involved participants not receiving tuberculosis treatment, specificity increased from 86% to 89% (Kohli 2018). We considered the type of culture used in the included studies because liquid culture is more sensitive than solid culture (American Thoracic Society 2000). Most studies used liquid culture or a combination of solid and liquid culture. The single study evaluating Xpert Ultra used liquid culture. Only two of the 15 studies (13%) evaluating Xpert MTB/RIF exclusively used solid culture. Culture results may also be negative owing to ine icient specimen collection or errors in sampling, di ering bacterial load, and contamination (Wright 2009b). Negative culture results in lymph node tuberculosis have previously been reported (Fontanilla 2011). Another reason for negative culture results is that there may have been a decrease in live tuberculosis bacteria during processing with N-acetyl-L-cysteine-sodium hydroxide, which is routinely used to homogenize, decontaminate, and liquefy non-sterile specimens, such as sputum, for mycobacterial culture (American Thoracic Society 2000). Harsh decontamination practices have been noted to contribute to false-negative culture results, especially in paucibacillary specimens (FIND 2017). Standards specify, "specimens collected from normally sterile sites may be placed directly into the culture medium" (American Thoracic Society 2000). CSF, pleural fluid, and lymph node aspirates are usually considered to be sterile specimens. It is our understanding that some laboratories do decontaminate sterile site specimens as a precaution against non-sterile collection procedures. In this review, 47% of the studies reported decontaminating lymph node aspirates before culture inoculation. We did not have su icient data to further investigate laboratory practices. In summary, several factors probably contributed to low Xpert MTB/ RIF specificity against culture in lymph node aspirate. The 'true' specificity of Xpert MTB/RIF in lymph node aspirate is likely to be higher owing to the aforementioned reasons. Xpert MTB/RIF specificity was higher against a composite reference standard and with application of latent class analysis, similar to that found in CSF, pleural fluid, and other specimens ( Table 2; Table 3 ). We investigated the prevalence of extrapulmonary tuberculosis (confirmed by culture) as a potential source of heterogeneity because changes in disease prevalence have o en been found to be associated with other important changes, such as changes in the disease spectrum, which may a ect diagnostic accuracy estimates (Leeflang 2013). For Xpert MTB/RIF, for pleural fluid and lymph node aspirate, we found that pooled sensitivity was higher in settings with higher tuberculosis prevalence. In all analyses, for both Xpert Ultra (CSF) and Xpert MTB/RIF (CSF, pleural fluid, and lymph node aspirate), specificity in settings with higher tuberculosis prevalence was similar or lower than in settings with lower tuberculosis prevalence. Findings from additional analyses are available in the previous version of this review (Kohli 2018). (Summary of findings 4) Results of these studies indicate that in theory, for a population of 1000 people where 100 have rifampicin resistance, 100 would This review represents the most comprehensive review of the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis in adults. For Xpert MTB/RIF, our previous review (Kohli 2018) provides additional findings. These reviews provide evidence that may help countries to make decisions about scaling up the tests for programmatic management of tuberculosis and drug-resistant tuberculosis. Although the information in this review will help to inform such decisions, other factors such as resource requirements and feasibility (including stable electrical power supply, temperature control, and maintenance of the cartridge modules) will also be important considerations. This is a reasonably complete data set. We included any non-English studies that we found from which we could obtain accuracy data. However, we acknowledge that we may have missed some studies despite the comprehensive search and our outreach to investigators. We included eight common forms of extrapulmonary tuberculosis in the review. However, for some of these forms, such as disseminated tuberculosis, data were insu icient to allow us to determine summary accuracy estimates. We did not include less common forms, such as cutaneous tuberculosis, ocular tuberculosis, female genital tuberculosis, and tuberculosis of the breast. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy (PRISMA-DTA) (McInnes 2018). In a systematic review of diagnostic test accuracy studies, the reference standard is the best available test to determine the presence or absence of the target condition. In this review, we used two reference standards: culture and a composite reference standard, both of which are known to be imperfect. While the composite reference standard is designed to have improved accuracy compared to culture alone, it may still lead to biased accuracy estimates of the index test, depending on various factors such as the accuracy of the di erent components; decision rules for combining them; prevalence of the target condition; and conditional dependence between the components and the index test (Schiller 2016). Conditional dependence between two imperfect tests arises when both tests make the same false-positive or false-negative errors more o en than expected by chance (Naaktgeboren 2013). Hence, conditional dependence may arise between the index test and both reference standards we have used, as they are imperfect. As a consequence, we may overor underestimate the diagnostic accuracy of the index tests. An additional challenge with including a composite reference standard is that the definition of the composite reference standard may vary across studies, making it di icult to interpret the accuracy Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews estimates. To adjust for the imperfect accuracy of culture, we applied a latent class model when evaluating Xpert MTB/RIF sensitivity and specificity, for which there were a larger number of studies. We added parameters for the sensitivity and specificity of culture and terms for conditional dependence to adjust for the dependence between Xpert MTB/RIF and culture among diseasepositive and disease-negative participants. In this way, we were able to improve estimation of both the pooled sensitivity and specificity of Xpert MTB/RIF, as well as between-study variability. An adequate number of studies is needed for a su iciently robust model to estimate these additional parameters. We therefore found that we were unable to do the same for meta-analyses of the accuracy for Xpert Ultra owing to the small number of studies, many of which had small sample sizes resulting in zero cell counts. Several factors may have contributed to false-negative culture results for the accuracy of the reference standard for lymph node aspirate in particular, including ine icient specimen collection and overly harsh decontamination. For this particular analysis, we were able to take advantage of the Bayesian estimation approach to incorporate prior information on Xpert MTB/RIF and culture specificity. This allowed us to make the best use of data from the included studies and our knowledge of the performance of Xpert MTB/RIF. We had insu icient data to apply the latent class model to data from the single study evaluating Xpert Ultra in lymph node aspirates. Establishing a diagnosis of extrapulmonary tuberculosis would ideally include pursuing the diagnosis of pulmonary tuberculosis as well, because participants with tuberculosis may have both pulmonary and extrapulmonary tuberculosis and the lung may be the only site where the presence of tuberculosis can be established. Because of the di iculties involved in diagnosing HIVassociated tuberculosis, it is recommended that multiple cultures from sputum and other types of specimens be evaluated in people living with HIV (Bjerrum 2019; Shah 2016b). Given the limitations in the reference standard, we recommend that future studies consider using liquid culture because this is more sensitive than solid culture, and that researchers obtain multiple specimens for culture to confirm the diagnosis of extrapulmonary tuberculosis (Drain 2019). Most studies included in this review used culture-based DST (either Löwenstein-Jensen (LJ) or mycobacteria growth indicator tube (MGIT) 960) as the reference standard for detection of rifampicin resistance. Concerns have been raised about rapid DST methods, in particular automated MGIT 960, for tuberculosis drug resistance using the recommended critical concentrations. The WHO is planning to prioritise a re-evaluation of the critical concentrations for rifampicin (WHO 2018). We assessed the number of specimens with nontuberculous mycobacteria (NTMs) that were Xpert Ultra-positive. In two studies that reported 120 NTMs, Xpert Ultra was negative in all specimens. In the previous version of this review, among 10 studies that reported information comprising 141 NTMs, Xpert MTB/RIF was negative in all specimens (Kohli 2018). Risk of bias was low for the participant selection, index test, and flow and timing domains and was high or unclear for the reference standard domain (most of these studies performed specimen decontamination before culture inoculation). A limitation was that several studies included more than one specimen per participant, which artificially inflated the sample size of the study and may have led to overestimation or underestimation of the accuracy estimates. In general, studies were fairly well reported, although we corresponded with almost all primary study authors to ask for additional data and missing information. In several studies, accuracy data by site of extrapulmonary disease were not reported, and in a minority of studies, blinding was not reported. We strongly encourage the authors of future studies to follow the recommendations provided in the updated Standards for Reporting Diagnostic Accuracy (STARD) statement to improve the quality of reporting (Bossuyt 2015). We investigated potential sources of heterogeneity in the di erent extrapulmonary specimens. Importantly, we found slightly higher Xpert Ultra accuracy in studies with concentrated cerebrospinal fluid (CSF) in comparison to unconcentrated specimens. We note that subgroup findings should be interpreted with caution, as there were only three studies and a small number of tuberculous meningitis cases included in these analyses. We are aware of several systematic reviews previously published on this topic that estimated summary accuracy of Xpert MTB/ RIF for distinct forms of extrapulmonary tuberculosis, as well as di erent forms of extrapulmonary tuberculosis combined (Table 8 ). We identified one systematic review that estimated summary accuracy of Xpert Ultra that found, for all forms of extrapulmonary tuberculosis combined, pooled sensitivity and specificity of 85.1% (95% CI 76.7 to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), (7 studies; 1500 specimens) (Zhang 2020). Compared with previous systematic reviews, our review extends the date of the search for potential studies for inclusion. Our strict inclusion criteria, e.g. excluding case-control studies, meant that some of the studies included in other reviews were excluded from ours. For the participant selection domain, most studies had high or unclear concern for applicability because either participants were evaluated exclusively as inpatients in tertiary care or we were not sure about the clinical settings. We therefore cannot be sure about the applicability of our findings to primary care. Studies that take place in referral settings may include participants whose condition is more di icult to diagnose than are seen at lower levels of the health system. However, we recognize that classifying studies as primary, secondary, or tertiary care may not adequately account for di erences in disease spectrum (Leeflang 2013). For the index and reference test domains, most studies had low concern for applicability. In people presumed to have extrapulmonary tuberculosis, Xpert Ultra and Xpert MTB/RIF may be helpful in confirming the diagnosis. Sensitivity varies across di erent extrapulmonary specimens, while for most specimens specificity is high, the test rarely yielding a Future studies should perform comparisons of di erent tests, including Xpert Ultra, as this approach will reveal which tests (or strategies) yield superior diagnostic accuracy. For these studies, the preferred study design is one in which all participants receive all available diagnostic tests or are randomly assigned to receive one or another of the tests. Studies should include children and people living with HIV. Future research should acknowledge the concern associated with culture as a reference standard in paucibacillary specimens, and should consider ways to address this limitation. Rapid point-of-care diagnostic tests for extrapulmonary tuberculosis are critically needed. Research groups should focus on developing diagnostic tests and strategies that use readilyavailable clinical specimens, such as urine, rather than specimens that require invasive procedures for collection. (7):544-54. Telenti Vonasek 2020 Vonasek B, Ness T, Takwoingi (7):e199-e210. Webster AS, Shandera WX. The extrapulmonary dissemination of tuberculosis: a meta-analysis. International Journal of Mycobacteriology 2014;3:9-16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155 (8):529-36. World Health Organization. Guidelines for treatment of tuberculosis, fourth edition. who.int/tb/ publications/2010/9789241547833/en/ 2010 (accessed 2 July 2020). World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test. Technical and operational 'Howto'. Practical considerations. who.int/tb/publications/tbamplificationtechnology-implementation/en/ 2011 (accessed 2 July 2020). World Health Organization. Updated interim critical concentrations for first-line and second-line DST (as of May 2012). www.stoptb.org/wg/gli/assets/documents/Updated %20critical%20concentration%20table_1st%20and%202nd %20line%20drugs.pdf 2012 (accessed 2 July 2020). World Health Organization. Xpert MTB/RIF implementation manual. Technical and operational 'how-to' practical considerations. apps.who.int/iris/ bitstream/10665/112469/1/9789241506700_eng.pdf 2014 (accessed 2 July 2020). World Health Organization. Guidelines for the treatment of drug-susceptible tuberculosis and patient care (2017 update). www.who.int/tb/publications/2017/dstb_guidance_2017/en/ 2017 (accessed 1 April 2020). World Health Organization. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis (WHO/CDS/TB/2018.5). who.int/tb/publications/2018/ WHO_technical_report_concentrations_TB_drug_susceptibility/ en/ (accessed 2 July 2020). Cochrane Database of Systematic Reviews Compendium_WHO_guidelines_TB_2017/en/ (accessed 2 July 2020). World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis -rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-consolidated-guidelineson-tuberculosis-module-3-diagnosis---rapid-diagnostics-fortuberculosis-detection 2020 (accessed 2 July 2020). World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment -drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/ item/9789240007048 (accessed 2 July 2020). World Health Organization. The END TB strategy. www.who.int/ tb/strategy/end-tb/en/ 2014 (accessed 1 April 2020). World Health Organization. Global Tuberculosis Report 2020. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2020. World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis -rapid diagnostics for tuberculosis detection. Licence: CC BY-NC-SA 3.0 IGO. who.int/publications/i/item/who-operational-handbook-ontuberculosis-module-3-diagnosis---rapid-diagnostics-fortuberculosis-detection (accessed 6 August 2020). World Health Organization. Cochrane Database of Systematic Reviews Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Notes "A high proportion of participants had tuberculosis investigations prior to referral and the frequency of positive results were: sputum Xpert 3/22, urinary LAM 1/5, and tuberculosis culture (5/15) (by site: urine 0/1, blood 1/2, sputum 4/12, lymph node 0/1 (tissue)). Chest x-ray had been performed in 36% and reported as 'suggestive of tuberculosis' by the referring clinician in 28% of these." Risk of bias Applicability concerns Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Were the index test results interpreted without knowledge of the results of the reference standard? Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Antel 2020 (Continued) Cochrane Database of Systematic Reviews Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Antel 2020 (Continued) Cochrane Database of Systematic Reviews Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Azevedo 2018 (Continued) Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Could the conduct or interpretation of the index test have introduced bias? Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Were the index test results interpreted without knowledge of the results of the reference standard? Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Low risk Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Unclear Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Blaich 2014 (Continued) Unclear Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Causse 2011 (Continued) Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Che 2017 (Continued) Unclear Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes High Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low risk High Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Chin 2019 (Continued) If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Christopher 2013 (Continued) Unclear DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Cresswell 2018 (Continued) Low concern DOMAIN 2: Index Test (Xpert Ultra) Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Cresswell 2020 (Continued) Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low risk High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Low risk Yes If a threshold was used, was it pre-specified? Yes Low concern Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Du 2015 (Continued) Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Cochrane Database of Systematic Reviews Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Ghariani 2015 (Continued) If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Hanif 2011 (Continued) Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Heemskerk 2018 (Continued) Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Hillemann 2011 (Continued) Yes If a threshold was used, was it pre-specified? Yes Low risk Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Was a consecutive or random sample of patients enrolled? Unclear Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Was a consecutive or random sample of patients enrolled? Unclear Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Cochrane Database of Systematic Reviews these patients are routinely referred from the primary health care clinic to the referral centre for FNAB (fine needle aspiration biopsy)" Risk of bias Applicability concerns Was a consecutive or random sample of patients enrolled? Yes Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Lusiba 2014 (Continued) Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Low risk Patient Sampling Cohort, consecutive, prospective Patient characteristics and setting Presenting signs and symptoms: patients with any TB symptoms including any cough, fever, night sweats, loss of weight, haemoptysis or chest pain or both, and features consistent with a pleural effusion on chest x-ray Cochrane Database of Systematic Reviews Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Unclear Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Metcalf 2018 (Continued) Patients on treatment may have been included, although the number was not reported: "Of the two specimens that were smear-positive and smear-negative on both culture and Xpert, one was pleural fluid from a patient who had been receiving Category II anti-tuberculosis treatment for 2 months and the other was pus aspirated from an axillary lymph node" Risk of bias Applicability concerns DOMAIN If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Nataraj 2016 (Continued) Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? High DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Low concern Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Pandie 2014 (Continued) Low concern DOMAIN 2: Index Test (Xpert MTB/RIF) Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Library Trusted evidence. Informed decisions. Better health. Was a case-control design avoided? Yes Did the study avoid inappropriate exclusions? Yes Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? No Cochrane Database of Systematic Reviews Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Yes Did all patients receive the same reference standard? Yes Were all patients included in the analysis? Yes Sarfaraz 2018 (Continued) Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing After a lumbar puncture was completed, study sta identified patients from the microbiology laboratories who had 3 ml of excess CSF remaining after routine testing composed of Gram stain, India ink stain, cryptococcal antigen testing, and bacterial culture on a blood agar plate. A composite reference standard was defined as probable TB meningitis = patients with a CSF white blood cell count between 10 and 500, CSF total protein of 100 mg/dl, and CSF glucose of 40 mg/dl. These values were adapted from a uniform case definition of probable TBM for use in clinical research (Marais 2010). However, sensitivity and specificity were only determined using culture as the reference standard Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Unclear Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Are there concerns that the included patients and setting do not match the review question? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern Was there an appropriate interval between index test and reference standard? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Are there concerns that the index test, its conduct, or interpretation differ from the review question? Were the index test results interpreted without knowledge of the results of the reference standard? Yes If a threshold was used, was it pre-specified? Yes Are there concerns that the index test, its conduct, or interpretation differ from the review question? Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Was there an appropriate interval between index test and reference standard? Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern DOMAIN 2: Index Test (Xpert Ultra) Is the reference standards likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index tests? For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? Could the reference standard, its conduct, or its interpretation have introduced bias? Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern DOMAIN 4: Flow and Timing Cochrane Database of Systematic Reviews quiring drainage. Pleuro-pulmonary tuberculosis, in which parenchymal lung involvement is visible on a chest X-ray, is associated with higher mortality than isolated pleural infection, which appears to be rarely fatal (Shu 2011) needle, with or without ultrasound guidance Lymph node tuberculosis, also called TB lymphadenitis Tuberculosis of the lymph nodes may affect one node or a group of nodes, or multiple groups within a chain. Lymph node tuberculosis is relatively more common among children than adults. The most common presentation is of a single, firm, non-tender enlarged node in the neck, although any lymph node group can be affected. This may be accompanied by fever, weight loss, and night sweats, particularly in people with HIV. Patients with tuberculosis in deep lymph nodes, such as the mediastinal or mesenteric lymph nodes, may present with fever, night sweats, and weight loss, or, more rarely, with symptoms related to compression of adjacent structures. Over time lymph nodes become fluctuant and may discharge via a sinus to the skin or an adjacent viscus. It should be noted that lymphadenopathy may also be seen in other forms of tuberculosis as part of the immune response, but this is not usually caused by direct infection of the lymph nodes Fine-needle aspiration of fluid from affected lymph node, with or without radiological guidance; surgical biopsy of superficial lymph nodes; endoscopic biopsy of deep lymph nodes with ultrasound guidance Bone or joint tuberculosis Tuberculosis of bones or joints or both causes chronic pain, deformity, and disability, and tuberculosis of the cervical spine can be life-threatening. The usual presenting symptom is pain. Fever and weight loss, with or without signs of spinal cord compression, may be present. Patients with advanced disease may have severe pain, spinal deformity, paraspinal muscle wasting, and neurological deficit. Children may have failure to thrive and difficulty walking Aspiration of joint fluid or periarticular abscesses; percutaneous computed tomography-guided biopsy of lesions is preferred, but some patients may require open biopsy Genitourinary tuberculosis Tuberculosis of the genitourinary tract includes renal tuberculosis and tuberculosis of the reproductive system. Renal tuberculosis presents with flank pain, haematuria, and dysuria. Female genital tuberculosis presents with infertility (and may be otherwise asymptomatic), pelvic pain, and vaginal bleeding. Testicular tuberculosis presents with a scrotal mass and infertility Urine; biopsy of affected organs, acquired under radiological guidance or surgically Pericardial tuberculosis, also called TB pericarditis Tuberculosis of the pericardium presents with fever, malaise, night sweats, and weight loss. Chest pain and shortness of breath are also commonly-experienced symptoms. Pericardial tuberculosis may be associated with pericardial effusion, which can be severe and lead to life-threatening tamponade. Some patients go on to develop pericardial constriction, which can lead to heart failure and death and may require surgical intervention even after mycobacterial cure Pericardial fluid acquired by pericardiocentesis; pericardial biopsy, acquired under radiological guidance or surgically Peritoneal tuberculosis Tuberculosis of the peritoneum usually presents with pain and abdominal swelling, which may be accompanied by fever, weight loss, and anorexia Ascitic fluid acquired by paracentesis; peritoneal biopsy (Chow 2002) Disseminated tuberculosis, also called miliary tuberculosis. It has been proposed that the designation 'miliary TB' be restricted to disseminated TB with miliary shadows on chest radiograph (Reuter 2009) Disseminated tuberculosis involves two or more distinctly separate sites. Manifestations may be varied, ranging from acute fulminant disease to non-specific symptoms of fever, weight loss, and weakness. HIV-positive people are more likely to have disseminated tuberculosis than HIV-negative people. In a systematic review of the prevalence of tuberculosis in post mortem evaluations of HIV-positive people, among adults disseminated tuberculosis was found in 88% of tuberculosis cases and was considered the cause of death in 91% of TB cases (Gupta 2015) Blood; specimens acquired from affected extrapulmonary sites Table 2 . Summary accuracy of Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis and rifampicin resistance (Continued) Abbreviations: Crl: credible interval; CSF: cerebrospinal fluid; LPA: Line probe assay; TB: tuberculosis. Studies included in the table are limited to those that report data for both sensitivity and specificity; thus the number of studies (specimens) may di er slightly from those reported in the main text of the review. For tuberculosis detection, the reference standard was culture and a composite reference standard. For rifampicin resistance detection, the reference standards were culture-based drug susceptibility testing or line probe assay. Pooled sensitivity and pooled specificity are posterior median estimates. Abbreviations: Crl: credible interval. We generally used non-informative priors in the latent class model. Accuracy estimates were determined using a bivariate random-e ects approach for comparison. Table 6 . Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity (Continued) Abbreviations: Crl: credible interval. Prevalence refers to the percentage of culture-confirmed tuberculosis specimens or confirmed rifampicin-resistant specimens in the study. We selected prevalence levels to approximate the lower bound of the interquartile range or in consideration of the range of prevalences reported in the included studies. Abbreviations: Crl: credible interval. • Review and update Background section, including supporting references to take account of any changes that may have occurred. This should include updating any new information and current policy debates on the topic This review update will describe the burden of extrapulmonary tuberculosis worldwide based on the latest WHO Global Tuberculosis Report. The Background will describe the updated WHO guidelines on molecular methods for diagnosing tuberculosis, including Xpert MTB/RIF and Xpert Ultra. The WHO Meeting to update the guidelines took place 3 -6 December 2019. This Cochrane Review update will have informed these guidelines • Review current PICO(s) and amend in light of new knowledge. • Identify any changes in usual-care standards. • Check for standardised core outcomes sets, such as those developed in collaboration with the core outcome measures in effectiveness trials (COMET) initiative (www.comet-initiative.org) or by guideline groups since the original review. • Check for any relevant patient-reported outcomes to include subsequent to the original review. • Consider any new studies with less risk of bias that might warrant a stricter study design inclusion criterion (where the older version, when there was a dearth of evidence, included observational or quasi-randomised comparisons). This is a diagnostic test accuracy review. Participants, index tests, and target condition, will be the same as in Kohli 2018 except as follows: The update will be restricted to adults (15 years and older). The reason for this is that we have a separate Cochrane Review underway that is evaluating the tests for extrapulmonary tuberculosis in children. We will add a composite reference standard, defined as culture or clinical criteria as defined by the primary study authors. The addition of a composite reference standard was specifically requested by the WHO and Guideline members. The primary objectives are to assess the diagnostic accuracy of Xpert Ultra for the diagnosis of extrapulmonary tuberculosis and to assess the diagnostic accuracy of Xpert Ultra for the detection of rifampicin resistance in adults. Secondary objectives are the following. -to investigate potential sources of heterogeneity in test accuracy, including volume of CSF for TB meningitis and processing methods for lymph node TB -to compare the accuracy of Xpert Ultra and Xpert MTB/RIF in studies that evaluated both tests. Concerning patient outcomes, the Discussion will summarize and refer to key findings in the test-treatment Cochrane Review by Haraka et al. (currently undergoing peer review). Although the Haraka review relates to pulmonary tuberculosis, it is the only evidence on patient outcomes of which we are aware. We will use QUADAS-2 to appraise methodological quality of included studies consistent with Kohli 2018. If data are sufficient, we will perform meta-analyses using a bivariate random-effects model. The analyses will include: Cochrane Database of Systematic Reviews The different forms (and corresponding specimens for diagnosis) of extrapulmonary TB include: tuberculous meningitis, lymph node tuberculosis, pleural tuberculosis, genitourinary tuberculosis, bone or joint tuberculosis. We will create 'Summary of findings' tables for the two primary objectives of the review. Cochrane Database of Systematic Reviews We considered this domain separately for the reference standard for detection of extrapulmonary tuberculosis and the reference standard for detection of rifampicin resistance. Signalling question 1: is the reference standard likely to correctly classify the target condition? For detection of extrapulmonary tuberculosis, culture is generally considered the best reference standard. However, limitations are associated with culture; bacterial load is usually low in extrapulmonary tuberculosis, leading to a reduction in the sensitivity of culture. Concerning the conduct of the reference standard (preparation of the specimen for culture), N-acetyl-L-cysteine-sodium hydroxide is routinely used to homogenize, decontaminate, and liquefy non-sterile specimens for TB culture (American Thoracic Society 2000). However, CSF, pleural fluid, and lymph node aspirates are usually considered sterile, and standards specify, "specimens collected from normally sterile sites may be placed directly into the culture medium" (American Thoracic Society 2000). Overly processing (sterile) specimens with N-acetyl-L-cysteine-sodium hydroxide may lead to a decrease in viable TB bacteria and consequently false-negative cultures. We scored "yes" if studies did not use N-acetyl-L-cysteine-sodium hydroxide for processing specimens and "unclear" if studies used N-acetyl-L-cysteine-sodium hydroxide. We discussed this further under Discussion and Strengths and weaknesses of the review. For detection of rifampicin resistance, culture-based drug susceptibility testing (DST, also called conventional phenotypic method) is considered to be the best reference standard. Line probe assays are also WHO-recommended tests for rifampicin resistance. As we extracted data only for studies that used culture-based DST or line probe assays (most o en MTBDRplus), we answered this question "yes" for all studies. Signalling question 2: were the reference standard results interpreted without knowledge of results of the index test? We scored "yes" if the reference test provided an automated result (e.g. MGIT 960), if blinding was explicitly stated, or if it was clear that the reference standard was performed at a separate laboratory and/or was performed by di erent people. We scored "no" if the study stated that the reference standard result was interpreted with knowledge of the Xpert Ultra or Xpert MTB/RIF test result. We scored "unclear" if we could not tell. We added a signalling question for rifampicin resistance detection. We scored "yes" if the reference test provided an automated result (e.g. MGIT 960), if solid culture was performed followed by speciation, if blinding was explicitly stated, or if it was clear that the reference standard was performed at a separate laboratory or was performed by di erent people, or both. We scored "no" if the study stated that the reference standard result was interpreted with knowledge of the Xpert test result. We scored "unclear" if we could not tell. Not all studies evaluated detection of rifampicin resistance; therefore this question was not applicable to all studies. We judged "high concern" if included studies did not speciate mycobacteria isolated in culture, "low concern" if speciation was performed, and "unclear concern" if we could not tell. If a study performed sequencing, we considered the speciation yes. If the study only used a composite reference standard, we considered applicability unclear. Signalling question 1: was there an appropriate interval between the index test and the reference standard? In most included studies, we expected that specimens for index test and verification by culture (or a composite reference standard) would be obtained at the same time, when patients were evaluated for presumptive extrapulmonary tuberculosis. However, even if there were a delay of several days between index test and reference standard, tuberculosis is a chronic disease, and we considered misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We judged "yes" if the index test and the reference standard were performed at the same time or if the time interval was less than or equal to seven days, "no" if the time interval was greater than seven days, and "unclear" if we could not tell. Signalling question 2: did all patients receive the same reference standard? For the diagnosis of any form of extrapulmonary tuberculosis we answered this question "yes" if all participants in the study or a subset of participants in the study (for whom we extracted data) received the acceptable reference standard either culture or a composite reference standard. Regarding culture, we acknowledge that it is possible that some specimens could undergo solid culture and others liquid culture as the reference standard. This could potentially result in variations in accuracy, but we think the variation would be minimal. For rifampicin resistance detection, we answered "yes" if all participants received the same reference standard (either culture-based DST or MTBDRplus), "no" if not all participants received the same reference standard, and "unclear" if we could not tell. Cochrane Database of Systematic Reviews Table 9 describes prespecified changes for this review update. Selection criteria: We included studies where at least 85% of the participants enrolled were adults, aged 15 years or older, with presumptive extrapulmonary tuberculosis or rifampicin-resistant tuberculosis from all settings and countries. Restricting the age group to adults di ers from the original review, where we also included children (Kohli 2018). We did this because children are now included in a separate Cochrane Review, Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Kay 2020). We excluded studies where we could not disaggregate data on adults from those in children and studies where we could not tell the age of the participants enrolled. QUADAS-2: we modified QUADAS-2 as follows. Participant selection domain, applicability: For tuberculous meningitis, owing to the severity of the illness, we judged 'low concern' if participants were evaluated as inpatients at tertiary care centres. In the original review, we judged tertiary care to be a setting of high concern. Reference standard domain: We clarified that CSF, pleural fluid, and lymph node aspirates are usually considered to be sterile, and standards specify that these specimens may be placed directly into the culture medium. Overly processing specimens may lead to falsenegative cultures. We scored 'yes' if studies did not use N-acetyl-L-cysteine-sodium hydroxide for processing sterile specimens and 'unclear' if studies used N-acetyl-L-cysteine-sodium hydroxide. Investigations of heterogeneity: For specimen volume, we restricted this analysis to CSF because it was most clinically meaningful. For other fluid specimen types, the manufacturer's instructions for sputum were usually followed, requiring 2 mL of input fluid for the Xpert cartridge. In terms of the WHO standard operating procedure for lymph node tissue, we did not investigate this further because 80% (8/10) of the included studies followed the WHO recommendations. In performing the review, it became clear that because a homogenization step is part of the WHO standard operating procedure for preparing tissue specimens, there was no need to perform an additional separate analysis to confirm the presence of a homogenization step. We removed condition of specimen (fresh or frozen) from the analysis, because we identified only six studies in the current review that used frozen specimens, and we had already performed an analysis of this possible source of heterogeneity for the Cochrane Review on Xpert for pulmonary tuberculosis (Steingart 2014). We have tried to eliminate stigmatizing language, for example, by changing 'suspected tuberculosis' to 'presumptive tuberculosis'. For Xpert Ultra accuracy for lymph node tuberculosis, owing to insu icient data, we were unable to investigate processing methods for lymph node aspirate. GRADE: We elaborated on the means of applying GRADE to publication bias: We rated publication bias as undetected (not serious) for several reasons: the comprehensiveness of the literature search and extensive outreach to tuberculosis researchers to identify studies; the presence of only studies that produced precise estimates of high accuracy despite small sample size; and our knowledge about studies that were conducted but not published. Unlike our previous review, in this update we did not extract information on manufacturers' involvement and funding. As both Xpert Ultra and Xpert MTB/RIF are available at a concessional price for researchers in resource-limited settings, and well-established tests, especially Xpert MTB/RIF, industry donation is rarely pursued. We acknowledge that, in addition to funding, there are other reasons for conflicts of interest, but we did not have time to pursue these. We are aware of a new tool being developed for this purpose: TACIT (Tool for Addressing Conflicts of Interest in Trials: tacit.one). We plan to avail ourselves of this new tool in future updates. Sensitivity analyses: We stated in our protocol that for Xpert Ultra we would perform a sensitivity analysis by limiting studies to those that included only untreated participants. This information was o en not reported in the publications and we did not contact primary study authors specifically about this question. We were therefore unable to confirm that studies met this criterion. For the 'Summary of findings' tables, we prioritised culture as the reference standard (best reference standard for tuberculosis), apart from lymph node aspirate where we provide evidence using a composite reference standard, because, based on findings from the original review (Kohli 2018), we believe a composite reference is preferable for estimating accuracy. We added post hoc a sensitivity analysis limiting inclusion to studies that used one specimen per participant. Antibiotics Sixty-seven studies evaluated Xpert MTB/RIF (Ablanedo-Terrazas Eleven studies evaluated Xpert Ultra. Of these 11 studies All studies but two (one in Spanish: Peñata 2016, and one in Turkish: Ozkutuk Xpert MTB/RIF for diagnosis of tuberculous cervical lymphadenitis in HIV-infected patients Diagnostic performances of the Xpert MTB/RIF in Brazil Ruiz 2017 {published data only} Evaluation of a new automated abbott realtime MTB RIF/INH assay for qualitative detection of rifampicin/isoniazid resistance in pulmonary and extra-pulmonary clinical samples of mycobacterium tuberculosis Age: 15 years and older Sex, female: pleural tuberculosis: 20%; TB meningitis: 44% Children: no HIV infection: 0% Clinical setting: national level tuberculosis referral centre Past history of TB: not reported Participants on anti-TB treatment: not reported Number of specimens evaluated: not reported Laboratory level: central Country: China World Bank Income Classification: middle income High TB burden country: yes High MDR-TB burden country: yes High TB/HIV burden country: yes Prevalence of TB cases in the study: Index tests Xpert MTB/RIF and Xpert Ultra Embase (OVID) Multidrug-Resistant/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Mycobacterium tuberculosis RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration Cochrane Database of Systematic Reviews 4 (extrapulmonary or extra-pulmonary or EPTB).ti. or (extrapulmonary or extra-pulmonary or EPTB) lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal or genitourinary or pericardial).ti. or (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal or genitourinary or pericardial) Male Genital/ or Tuberculosis, Spinal/ or Tuberculosis, Cutaneous/ or Tuberculosis, Urogenital/ or Tuberculosis, Osteoarticular/ or Tuberculosis, Endocrine/ or Tuberculosis, Renal/ or Tuberculosis, Splenic/ or Tuberculosis, Ocular/ or Tuberculosis, Laryngeal/ or Tuberculosis, Gastrointestinal/ or Tuberculosis/ or Tuberculosis, Meningeal/ or Tuberculosis, Oral/ or Tuberculosis, Pleural/ or Tuberculosis, Lymph Node/ or Tuberculosis Biosis previews TOPIC (tuberculosis or tuberculous) AND TOPIC: (extrapulmonary or extra-pulmonary or EPTB or lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal or genitourinary or pericardial) AND TOPIC: (Xpert* or Genexpert or cepheid) LILACS tuberculosis or tuberculous tuberculosis OR tuberculous ) AND TITLE-ABS-KEY ( extrapulmonary OR extra-pulmonary OR eptb OR lymphadenitis OR disseminated OR miliary OR pleur* OR skeletal OR spine OR mening* OR intracranial OR intra-ocular OR ocular OR abdominal OR genitourinary OR pericardial ) AND TITLE-ABS-KEY Cochrane Infectious Diseases Group Specialist Register; ClinicalTrials.gov, WHO ICTRP, ISRCTN registry, ProQuest Dissertations & Theses A&I tuberculosis and Xpert$; tuberculosis and Genexpert Study details Type of study: randomized controlled trial; cross-sectional cohort (with follow-up)status: low; middle; high II. Presenting signs and symptoms, setting Presenting signs and symptoms? Clinical setting: inpatient Intermediate: peripheral laboratory tests and culture on solid media and line probe assay (LPA) from smear-positive sputum Central: intermediate laboratory tests and culture on liquid media and DST (first-and second-line anti-TB drugs) on solid or in liquid media and LPA on positive cultures and rapid speciation tests III. Other demographics HIV patients included? yes; no; unclear/not reported; if yes ## and percentage? 15 years old) included: yes; no; unclear/not reported; if yes, percentage? Percentage female included? Unclear/not reported Past history of TB? yes; no; unclear/not reported; if yes, percentage? Only patients who received TB treatment for ≤ 7 days were included? yes; no; unclear/not reported; if no, percentage on treatment included? IV. Reference standard A. Reference standard for TB detection Solid culture (specify): LJ 7H10 7H11 RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration Cochrane Database of Systematic Reviews Liquid culture (specify): MGIT Bactec 460tissue, specify WHO followed: yes; no; unclear 2b. Other tissue homogenization step for tissue specimens: yes; no; unclear/not reported (For tissue, if WHO SOP not followed Grind solution of tissue and PBS until homogeneous suspension has been obtained Double volume of specimen with Xpert ® Sample Reagent (1.4 mL Sample Reagent to 0.7 mL of homogenized tissue) Shake tube vigorously 10 to 20 times or vortex for at least 10 seconds Incubate specimen for 10 minutes at room temperature, and again shake specimen 10 to 20 times or vortex for at least 10 seconds Mix the specimen and the Sample Reagent by vortexing as described above. A er seven to eight minutes at room temperature, vortex the sample as above a second time Incubate for an additional seven to eight minutes (15 minutes total incubation) at room temperature Load the cartridge into the GeneXpert instrument according to the manufacturer's instructions Body fluid: specify; fluid: specify; sample input volume: specify; unclear/not reported 5a. Body fluid: specify; processed as per manufacturer for sputum Yes/No/Unclear 5b. Body fluid: specify; sample input volume: specify; unclear/not reported (Add additional specimens as needed For body fluids other than CSF, if manufacturer's instructions not followed, briefly describe specimen processing in comments Pour or pipette (pipette not provided) approximately 2 times the volume of Sample Reagent into the specimen (2:1 dilution, Sample Reagent: specimen) Signalling question 3: did the study avoid inappropriate exclusions? We scored "yes" if the study included both smear-positive and smear-negative specimens or included only smear-negative specimens. We judged "no" if the study included only smear-positive specimens or excluded specimens based on physical appearance (such as purulence) or a biochemical analysis (e.g. adenosine deaminase (ADA), cytology (cell analysis)). We scored "unclear" if we could not tell. Applicability: are there concerns that the included patients and setting do not match the review question? We were interested in how the index tests performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. We scored "low concern" if patients were evaluated at local hospitals or primary care centres. We scored "high concern" if patients were evaluated exclusively as inpatients at tertiary care centres, except for tuberculous meningitis (we judged low concern) where we would expect patients to be evaluated in tertiary care settings. We scored "unclear concern" if the clinical setting was not reported or if information was insu icient to allow a decision. We also scored "unclear concern" if Xpert testing was done at a reference laboratory and the clinical setting was not reported for the following reason Signalling question 2: If a threshold was used, was it pre-specified? As the threshold is pre-specified in all versions of Xpert, we answered this question "yes" for all studies. Applicability: are there concerns that the index test, its conduct, or its interpretation di er from the review question? We note that variations in execution of the test might a ect accuracy estimates. We judged "low concern" if the test was performed according to WHO standard operating procedures (WHO 2014), or if the index test was performed as recommended by the manufacturer for sputum. We scored "high concern" if the test was performed in a way that deviated from these recommendations. We scored "unclear concern" if we could not tell. In studies that evaluated several di erent types of specimens, we used the following rule: if ≥ 75% of the specimen types were processed per WHO standard operating procedure (SOP) or as per the manufacturer's instructions, we judged and if at least 50% to 74% of the specimen types were processed per WHO SOP or as per the manufacturer's instructions, or if we could not tell We have no financial involvement with any organization or entity that has a financial interest in, or financial conflict with, the subject matter or materials discussed in the review apart from those disclosed MK received funding from USAID, administered by the World Health Organization Global Tuberculosis Programme, Switzerland. IS received funding from USAID, administered by the World Health Organization Global Tuberculosis Programme, Switzerland. ND's participation in this project was supported in part by the Canadian Institutes of Health Research MY's participation in this project was supported in part by the Canadian Institutes of Health Research. KD has no interests to declare CMD worked for the Foundation for Innovative New Diagnostics (FIND) until April 2019 and has no other interests to declare FIND is a not-for-profit foundation whose mission is to find diagnostic solutions to overcome diseases of poverty in low-and middle-income countries. FIND works closely with the private and public sectors and receives funding from donors and some of its industry partners. FIND has an independent Scientific Advisory Committee and organizational firewalls that protect it against any undue influences in its work or in publication of its findings. More information on FIND's policy and guidelines for working with private sector partners can be UK. She has received financial support from McGill University, Canada, and the World Health Organization (WHO) Global Tuberculosis Programme, Switzerland for the preparation of systematic reviews and educational materials, consultancy fees from Foundation for Innovative New Diagnostics (FIND), Switzerland (for the preparation of systematic reviews and GRADE tables), honoraria, and travel support to attend WHO guideline meetings USA Development of this project was in part made possible with financial support from USAID administered by the World Health Organization Global TB Programme • Canadian Institutes of Health Research (CIHR) grant PJT-156039: Evaluating diagnostic accuracy of tests and decision rules in the absence of a perfect reference test: application to extrapulmonary tuberculosis RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults Copyright © 2021 The Authors Was a consecutive or random sample of patients enrolled?Cochrane Database of Systematic Reviews Zmak 2013 (Continued) CSF: cerebrospinal fluid; DST: drug susceptibility testing; EBUS: endobronchial ultrasound; EPTB: extrapulmonary tuberculosis: IQR: interquartile ratio; LJ: Löwenstein-Jensen; LN: lymph node; MDR-TB: multi-drug-resistant tuberculosis; MGIT: mycobacteria growth indicator tube; NALC-NaOH: N-acetyl-L-cysteine-sodium hydroxide; SD: standard deviation; SOP: standard operating procedure; TB: tuberculosis; TBM: tuberculous meningitis; WHO: World Health Organization. Cochrane Database of Systematic Reviews Presented below are all the data for all of the tests entered into the review. Tuberculous meningitis Tuberculosis of the meninges affects people of all ages but is most common among children and people with untreated HIV infection. In adults, tuberculous meningitis presents with gradual onset of headache, neck stiffness, malaise, and fever, and if untreated can progress to altered sensorium, focal neurological deficits, coma, and death. Young children may present with poor weight gain, low-grade fever, and listlessness. Infants may present with fever, cough (related to the primary pulmonary infection that occurs before tuberculous meningitis develops), change of consciousness at presentation, bulging anterior fontanel, and seizures (Thwaites 2013). Tuberculous meningitis is sometimes associated with a concurrent cerebral tuberculoma, or, more rarely, a tuberculous abscess Comments on specimen processing. Specimen collected from sterile site: Yes/No/Unclear Specimen processed for culture as per American Thoracic Society Diagnostic Standards? Yes/No/Unclear (ATS guidelines: specimens collected from normally sterile sites may be placed directly into the culture medium.)Note: All specimens such as CSF, pleura, lymph node aspirates and tissues, peritoneal fluid, pericardial fluid, bone or joint fluid and tissue, and urine are considered sterile. Cochrane Database of Systematic Reviews We determined the answer to this question by comparing the number of patients enrolled with the number of patients included in the 2 × 2 tables. We answered "yes" if the numbers matched and "no" if there were patients enrolled in the study who were not included in the analysis. We answered "unclear" if we could not tell.Judgements for overall ʽRisk of bias' assessments.• If we answered all signalling questions for a domain "yes", then we scored risk of bias as "low".• If we answered all or most signalling questions for a domain "no", then we scored risk of bias as "high".• If we answered only one signalling question for a domain "no", we discussed further the "risk of bias" judgement.• If we answered all or most signalling questions for a domain "unclear", then we scored risk of bias as "unclear".• If we answered only one signalling question for a domain "unclear", we discussed further the "risk of bias" judgement for the doma In this section we provide OpenBUGS models for the bivariate meta-analysis as well as the latent class meta-analysis. Any alternative prior distributions used are provided in the comments within each model.